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1 INTRODUCTION  
During the last years, considerable efforts in genetic research yielded 
many up to then unknown observations that can be summarized in one idea: 
epigenetics. This term refers to changes in gene expression without affection of 
the DNA sequence of an organism. (BIRD, 2007) The major characteristic of 
epigenetic events is that they can be passed on not only from cell to cell but 
also from organism to organism, i. e. the changes are heritable. (JABLONKA & 
LAMB, 1989) Such events may have considerable influence on the 
differentiation of cells, the phenotypical development of an organism and 
eventually the evolutionary progress of a population or species.  
The meaning of epigenetics has not always been consistent. In 1957 
Conrad H. Waddington defined epigenetics as the formation of a phenotype due 
to environmental influences on a certain genotype. (WADDINGTON, 1957) In 
the 1970s this theory was expanded by Holliday and Pugh who suggested that 
chemical DNA modification in form of cytosine methylation was the molecular 
background of Waddington’s hypothesis. (HOLIDAY & PUGH, 1975) Later, by 
the end of the 20th century, Riggs and colleagues established the current 
definition of epigenetics as “the study of mitotically and/or meiotically heritable 
changes in gene function that cannot be explained by changes in DNA 
sequence”. (RUSSO & al., 1996) This definition clearly points out that various 
mechanisms are at work which do not lead to mutational changes of DNA, but 
still have an impact on whether and when genes are expressed. More 
definitions have been created, all giving respect to observations that many 
constituents of the cell nucleus seem to influence gene expression. (BIRD, 
2007) 
The involved mechanisms are quite numerous (FRASER & 
BICKMORE, 2007; ALTUCCI & STUNNENBERG, 2009), ranging from 
influences on nucleobases, e. g. the methylation of cytosine, the chemical 
modification of histones (FAN & al., 2008), the structure of chromatin 
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(BERGER, 2007) and the transcription of non-coding types of RNA. (GUIL & 
ESTELLER, 2009) The variety of possibilities is high. For example there are 
about 60 known modifications of histones. Methylation, acetylation, 
phosphorylation and ubiquitinylation are only some of them. Histones are 
globular proteins around which the DNA is wrapped, forming a structure similar 
to a pearl chain. One histone ‘carries’ 146 base pairs of double-stranded DNA 
and such a unit is called nucleosome. Histones are normally octameres 
consisting of one dimer of each of the subtypes H2a, H2b, H3 and H4, 
respectively. The histone spheres have a ‘tail’ whose lysine and arginine 
residues are typically subject to modification, whereas the kind of modification 
and the position of a certain residue can be correlated with the status of a gene, 
i. e. activation or repression of expression. Acetylation of lysine, methylation of 
arginine and phosphorylation of serine and threonine are generally linked to 
activation, in contrast to methylation of lysine that can be linked to activation 
and repression, depending on the position of lysine. (BERNSTEIN, 2007; 
KOUZARIDES, 2007) 
Histone modification is connected to the state of chromatin, meaning 
that epigenetic properties can be attributed to the latter. Chromatin is the series 
of nucleosomes that eventually makes up a chromosome. In general, 
acetylation of histones leads to a loose and more ‘open’ structure termed 
euchromatin. In contrast, other modifications and deacetylation lead to a packed 
structure termed heterochromatin. Euchromatin contains the majority of genes 
and unique DNA sequences, because its structure makes it accessible for the 
enzymical transcription machinery. The nucleosomes of heterochromatin, in 
contrast, are highly condensed, making it more difficult for the transcription 
machinery to gain access. Consequently, few genes and many repetitive DNA 
sequences can be found in heterochromatic regions. During mitosis and 
meiosis euchromatic structures are located at the chromosomal arms, whereas 
heterochromatic structures are located at the centromere and the telomeres of a 
chromosome. (GREWAL & ELGIN, 2007) 
According to modern definitions, the long known cellular mechanism of 
alternative splicing could also be described as epigenetic, even though it is 
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generally not included in the current literature on the topic. Alternative splicing 
means that expendable sequences of incomplete messenger RNA (so-called 
introns) need not always be excised in the same way. This leads to a different 
protein version, even though no changes ever occurred in the associated gene. 
(KARP, 2007) Thus alternative splicing might be included into the series of 
epigenetic mechanisms. The RNA interference pathway by which micro RNA 
(miRNA) is used to regulate and eliminate cellular transcripts or foreign RNA, 
respectively (KARP, 2007; GUIL & ESTELLER, 2009), would also fall into this 
category. 
One of the most important epigenetic factors is the methylation of DNA, 
especially the nucleobase cytosine. Such modification is known to be potentially 
inheritable and can have remarkable consequences for the phenotype and 
health of an organism, depending on the location of the particular nucleotide. 
(BIRD, 2002) This phenomenon’s potential molecular mechanisms and the 
methodology of cytosine methylation analysis will be the topic of the following 
work.  
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2 GENERAL ASPECTS OF DNA 
METHYLATION 
Another definition of epigenetics by Bird resumes this phenomenon as 
“the structural adaptation of chromosomal regions so as to register, signal or 
perpetuate altered activity states”. (BIRD, 2007) More likely than the former 
definitions, this one pronounces the biological significance of epigenetic 
processes. Nevertheless it does not differentiate between DNA methylation and 
other single epigenetic phenomena of distinct nature which can be related by 
biochemical processes in a given cell or organism. 
DNA methylation is a feature of a number of multi-cellular eukaryotic 
organisms. Mammalian genomes exhibit rather specialised functions of DNA 
methylation, such as ‘genomic imprinting’ (IDERAABDULLAH & al., 2008) and 
‘metastable epialleles’. (DOLINOY & al., 2007) Both phenomena will be 
discussed in the according chapters. Moreover, the enzymatic pathways for 
establishing methylation marks and removing them show broad variations, 
especially between the animal and the plant kingdom. (GOLL & BESTOR, 
2005) Here as well, the major differences will be pointed out in the according 
chapters. 
The quantitative range of DNA methylation is dramatically diversified. In 
the DNA sequence of the solitary cell organism Saccharomyces (yeast) or the 
nematode Caenorhabditis elegans, both serving as popular models for genetic 
and metabolic studies, no methylation has been detected and neither has any 
according enzymatic activity been identified. (HENDRICH & TWEEDIE, 2003) 
Another multi-cellular model organism, the fruit fly Drosophila melanogaster, 
exhibits low levels of methylation and an enzyme similar to the known 
methylating enzymes has been discovered. (LYKO & al., 2000) On the other 
hand, plant and vertebrate animal organisms possess the highest quantity of 
methylation marks and the highest degree of diversification within their 
respective genomes. (BIRD, 2002) 
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To date the only nucleotide known to be able to accept a methyl group 
is cytosine. By the enzymatic addition of a methyl group to the carbon atom of 
position 5 of the pyrimidine ring, 5-methyl cytosine (5mC) is created. (GOLL & 
BESTOR, 2005) For the chemical mechanism of this conversion, see the 
according chapter. Cytosine can be located within various nucleotide contexts. 
The most common is the 5’ addition of guanine. A frequent occurrence of this 
dinucleotide sequence in a certain DNA sequence is commonly referred to as 
CpG island. Other sequence contexts are CpT, e. g. present in D. melanogaster 
genomes, and CpNpG, a common trinucleotide sequence in plants, whereas N 
stands for an arbitrary nucleotide. (BIRD, 2002) 
The pattern of cytosine methylation varies distinctly among organisms 
as well. In general, non-vertebrate organisms exhibit mosaic methylation 
patterns, as was observed in the sea squirt Ciona intestinalis. (SIMMEN & al., 
1999) A mosaic pattern means a series of highly methylated DNA sequences 
that take respective turns with unmethylated sequences. In contrast, cytosine 
methylation in vertebrate genomes is spread across the DNA sequence. 
(COLOT & ROSSIGNOL, 1999) Especially in mammalian organisms there even 
exists a temporal variation of methylation marks, which is a crucial factor for the 
development of a respective organism during all phases of its life. Early 
embryonal development in mice, serving as a model organism for mammals, is 
associated with a higher decrease of methylation marks than other animals. 
(KAFRI & al., 1992) Details will be discussed in the according chapters. 
CpG islands are mostly located within gene promoters. This suggests a 
role for cytosine methylation in gene expression. Indeed, numerous 
experiments have shown that heavily methylated CpG islands within the 
promoter region of a given gene are associated with a repressed state of this 
gene. (BIRD & WOLFFE, 1999) Moreover, CpG island methylation appears to 
play a general role in genomic stability. In somatic human cells around 70-80% 
of all CpG islands located across the DNA sequence are affected by cytosine 
methylation. The variety of methylation marks applies to genes, as well as 
repetitive or satellite sequences and transposable elements. The latter 
observations lead to the assumption that methylation is not only a way to 
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suppress gene activity, but moreover to stabilize the genome by repressing all 
potentially hazardous DNA sequences. (BIRD, 1995; YODER & al., 1997A) In 
summary, cytosine methylation is both a path to the differentiated state of a cell 
and a mechanism to keep the genome in a stable and employable state. 
Probably the most striking observation in connection with DNA 
methylation is induced by the definition of Riggs, but excluded in the definition 
of Bird. This is the potential heritability of changes in gene activity or repression 
by epigenetic mechanisms, not only from cell to cell, but from one organism to a 
succeeding one. Whereas not much is known about properties of heritability of 
histone modification, this has particularly been shown for methylation marks. 
(BIRD, 2007) Moreover, the germ lines of an organism can be affected without 
phenotypical changes, whereas phenotypical changes can become visible in 
offspring generations. The model organism of the Agouti mouse has revealed 
striking evidence in this regard. (MORGAN & al., 1999) The exact context will 
be discussed in the according chapter. Such notice has not been taken for other 
epigenetic phenomena, making the methylation of cytosine a promising 
candidate for the research on influences of lifestyle, diet and environment on 
the physiological and pathological development of humans and animals and 
potential impacts on their respective progeny. 
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3 MOLECULAR MECHANISMS OF DNA 
METHYLATION 
3.1 Cytosine methylation 
Basically, there are two different versions of DNA methylation. First, 
there is maintenance methylation by which a newly synthesized DNA strand 
becomes methylated according to the already methylated original strand. This 
way of methylation typically occurs in the course of DNA synthesis before cell 
division. Next to maintenance methylation there is de novo methylation by which 
methyl-groups are added to DNA strands with low levels of or without 
methylation. (CHEN & LI, 2004) This procedure is characteristic for embryonic 
stem cells in which gene expression is programmed by epigenetic processes. 
(NG & al., 2008)  
The enzymes that carry out the transfer of methyl groups in many eukaryotes 
are called DNA methyl transferases (DNMTs). There are several isoforms of 
these enzymes with different functions (CHEN & LI, 2004) as will be explained 
in the following chapters. Apart from DNMTs, there are several enzymes in non-
mammalian organisms with a similar function but marked differences in their 
structure. One example is the group of chromomethylases which are typical for 
the plant kingdom. (ZILBERMANN, 2008) 
DNMTs are divided into three families. There is the DNMT1 family 
which appears to be deeply connected with the DNMT3 family. Representatives 
of the DNMT2 family can be found in organisms with DNMT1 and DNMT3 
homologues, but there are several organisms containing only DNMT2 
homologues. The general function of these enzymes and their relatives is the 
catalysis of the transfer of a methyl-group to cytosine residues on the DNA 
strand. Favoured targets are CpG islands in regions outside of genes or in gene 
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promoters. However, DNMTs show remarkable differences in functional details, 
structure, appearance and evolutionary history. (BESTOR, 2000) 
Altogether there are 10 motifs equal to all known eukaryotic 
methyltransferases that are shared by prokaryotic enzymes of the same type 
(see Fig. 1). A structure motif of a protein is a region inside this protein whose 
sequence and three dimensional structure can also be found in other proteins 
with the same assumed function. The degree of variation is very small, which 
can be interpreted as an indicator of evolutionary conservation of an essential 
biological function. These motifs proved valuable for the identification of 
methyltransferases of higher organisms. A so-called target recognition domain 
(TRD) is located between the motifs VIII and IX. (TRAUTNER, 1988) It connects 
the enzyme to the major groove of the DNA double strand. Therefore motif IX 
organises the TRD and motif VIII serves as a DNA backbone and makes 
contact with the target cytosine. Motif VI contains the amino acid for the 
protonation of the N atom at position 3 of the cytosine (see below) and motif IV 
contains the catalytic region for covalent binding of a methyl group to the C5 
position of cytosine (see below). Eventually the motifs I and X bind the co-
enzyme S-adenosyl-L-methionine (SAM). SAM serves as the methyl group 
donor and the methionine part is reduced to homocysteine by the methylation 
reaction. (WILKE & al., 1988; CHENG & al., 1993; CAO & al., 2000) 
 
 
Fig. 1: DNMT motifs 
Common structural motifs of methyl-group transferring enzymes (GOLL & 
BESTOR, 2005) 
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By clarifying the molecular mechanisms of DNMT catalysis researchers 
were confronted with some difficulties. The reactivity of the C5 position in 
cytosine is very low, thus a basic covalent addition of a methyl group could not 
be assumed. Next to that, the amino acid structure around the catalytic centre is 
incompatible with the DNA double strand, so a solution for the steric issue had 
to be found as well. The latter problem was solved by the observation that the 
enzyme breaks the hydrogen bonds between the cytosine and the opposite 
thymidine and turns it around so that it fits into the catalytic centre (see Fig. 2).  
 
 
Fig. 2: Cytosine eversion 
Eversion of cytosine to be accessible to the methylation enzyme (GOLL & 
BESTOR, 2005) 
 
The next step is a covalent bond between the C6 position of cytosine 
and the thiol group of cysteine. Following this step, the N atom at position 3 
becomes protonated by a carboxyl group at the catalytic centre, forming an 
enamine structure between the positions C4 and C5. Before SAM comes into 
play, the protonation at position 3 is reversed and the double bond of the 
enamine moves back between positions 3 and 4. In the course of this procedure 
SAM provides a methyl group that is covalently added to the C5 position. The N 
at position 3 becomes protonated again and the H atom at the newly methylated 
position 5 is removed, which again moves the double bond between positions 4 
and 5. Eventually the original double bonds between positions 3 and 4, as well 
as 5 and 6 are restored by deprotonation of position 3 and removal of the 
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methyl transferase’s cysteine by beta-elimination (see Fig. 3). The newly 
synthesised 5-methyl-cytosine (5mC) can now serve its role as an epigenetic 
marker for whatever purpose. (CHENG & ROBERTS, 2001) 
 
 
Fig. 3: Enzymatic methyl transfer 
Reaction steps of the transfer of a methyl-group from cofactor to nucleotide by 
the methylation enzyme (GOLL & BESTOR, 2005) 
 
Remarkably, experiments showed that some organisms, like the plant 
Arabidopsis thaliana, have the potential of expressing at least 10 different 
versions of a methyl transferase, however, some invertebrates, like C. elegans 
or D. melanogaster, show hardly any signs of such an enzyme at all. (GOLL & 
BESTOR, 2005) 
3.1.1 DNMT1 
The first identified eukaryotic methyl transferase was DNMT1. (BESTOR 
& al., 1988) Observations showed that DNMT1 catalyses methylation of both 
unmethylated DNA double strands and DNA with one already methylated and 
one newly synthesised unmethylated strand. However, hemimethylated DNA 
was affected with up to 30-fold efficiency, depending on the substrate 
sequence. These results led to the conclusion that DNMT1 can be considered a 
maintenance methylation enzyme. However, the de novo methylation activity of 
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DNMT1 is greater than that of any other known methyl transferase, therefore it 
is assumed that its activity in an organism is restricted to maintenance 
methylation by additional to date unknown factors. Assuming DNMT1 as 
competent solely for maintaining DNA methylation, two possible activity models 
have been established. In the first model, DNMT1 is bound to proteins of the 
replication fork and therefore methylates hemimethylated sites parallel to DNA 
synthesis. The other model proposes factors independent of the replication 
process (see below). However, to date both models still lack consistency and 
will most probably be explicitly modified. (YODER & al., 1997B) 
DNMT1 is found in both embryonal and adult mammalian tissues. In a 
cell DNMT1 is present in the nucleus and in the cytoplasm. During the non-
replicative cell phases and after DNA replication the enzyme is located in the 
cytoplasm at very low concentrations, but it is imported into the cell nucleus 
before the S-phase. Located on the N-terminal region there is a domain for the 
import into the nucleus and a domain for making contact with the replication 
machinery. When a cell returns to normal metabolism after mitosis DNMT1 is 
degraded and the initiative sequence is again located on the N-terminal region. 
Moreover, there is at least on domain on the N-terminal region for the 
interaction with DNMT1-associated proteins, but the exact function is unclear.  
The structure of DNMT1 has first been determined from murine 
erythroleukemia (MEL) cells and the nucleotide sequence corresponding to the 
amino acid sequence has been compared to cDNA of other organisms. The 
mouse DNMT1 contains about 1600 amino acids of which 500 belong to the C-
terminal region and 1100 to the N-terminal region. Both regions are connected 
by a domain consisting of alternating glycine and lysine residues. 
(LEONHARDT & al., 1992) 
Comparison with other eukaryotic DNMT1 homologues showed 
similarities. All known DNMT1 enzymes possess a glycine-lysine-domain that 
connects the N- and the C-terminal region. The catalytic centre is located on the 
C-terminal region. DNMT1 contains two bromo-adjacent homology (BAH) 
domains which are supposed to have an interactive function with other proteins. 
In addition to these features there is a cysteine-rich domain on the N-terminal 
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region that can bind Zink ions. This domain is limited to mammalian DNMT1s 
and its function has yet to be determined. (CALLEBAUT & al., 1999) 
Loss of function of DNMT1 has several severe consequences, whereas 
two of them are quite remarkable. First, loss of function appears to result in 
slight defects in base mismatch repair, suggesting that DNA methylation could 
play a role in this phenomenon. (GUO & al., 2004) Second, transposons are 
activated at an unusually high level. Of all known methyl transferases DNMT1 is 
the only one in mammals to be demonstrated as a repressor of transposons. 
(WALSH & BESTOR, 1999) Furthermore, mice embryos and embryonic stem 
cells can grow normally in their stem cell state without DNMT1, but die due to 
apoptosis as soon as they are forced to differentiate. This might be because of 
the inability of maintaining DNA methylation of non-essential genes in 
differentiated cells and thus aberrant cell metabolism. (LEI & al., 1996) For the 
connection of DNMT1 expression and the state of DNA methylation in human 
and experimental tumours, see the according chapter. 
The lymphoid specific helicase (Lsh) in mice has been reported a 
cofactor for maintenance methylation. Mutations of the Lsh gene lead to severe 
phenotypic appearances and early death. In addition, about 50% demethylation 
occurs, mostly in repeated sequences. Lsh belongs to the protein group of 
Swi2/Snf2 and several members of this group have been identified as possible 
cofactors for cytosine methylation in diverse organisms. For example, ATRX 
and DDM1 encode proteins that act in some way in maintenance methylation in 
mammals and plants, respectively. Moreover, the proteins methyl-CpG-binding 
protein 2 (MeCP2) and the kinase cyclin-dependent kinase-like 5 (CDKL5) have 
been reported to directly bind to DNMT1. Concerning CDKL5, it is assumed that 
this kinase activates the methyl transferase by active phosphorylation. UHRF1 
is another cofactor for the maintenance methylation process. In a current model 
this protein is stated to bind DNMT1 and transport it to hemimethylated sites. 
(NAN & al., 1997; GEIMAN & al., 2001; KAMESHITA & al., 2008) 
Two special forms of DNMT1 shall be addressed in this chapter. One is 
the homologue located in oocytes which is therefore named DNMT1o. The N-
terminal domain responsible for degradation is missing in DNMT1, thus the 
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enzymes remains in the cytoplasm for a longer time by binding of the shortened 
sequence to annexin V. DNMT1o functions during embryo development as well, 
especially at the 8-cell-stage which has been referred to as a critical time to 
avoid demethylation. (DOHERTY & al., 2002; CIRIO & al., 2008) 
The other version similar to DNMT1 is the plant methyl transferase 
MET1, first identified in A. thaliana. (FINNEGAN & DENNIS, 1993) The C-
terminal region is about 50% equal with other DNMT1 homologues, the N-
terminal region about 25%. The preferred targets of MET1 appear to be CpG 
islands, but not CpNpG islands which are typical for plant genomes. In contrast 
to organisms in which DNMT1 is normally the only representative of its family, 
A. thaliana can express three more genes encoding isoforms of MET1. 
However, MET1 is the major enzyme of this group. Although experiments could 
not find any methylation activity in vitro, knock-out experiments and phenotypic 
assessments accounted MET1 for being a homologue of DNMT1. It is 
considered an enzyme for maintenance methylation, but shows properties of de 
novo methylation as well. (SAZE, 2008; ZILBERMANN, 2008) 
3.1.2 DNMT2 
DNMT2 is a puzzling methyl transferring enzyme. Although its 
prevalence is high among eukaryotes, to date studies failed to identify its exact 
function. Knock-out experiments on several organisms did not generate any 
obvious phenotypes, nor could any aberrations in DNA methylation or 
chromosome structure be detected. Additionally, in vitro experiments provided 
no or only negligible results concerning methylation of either double- or single-
stranded DNA. Structural analyses even bear doubt that the substrate of 
DNMT2 is double-stranded DNA. However, protein structure and thoroughly 
existent expression in adult mammalian tissues point out rather straight that the 
DNMT2 family has a methyl transferase function. It has been shown that 
DNMT2 catalyzes methylation of CpG, CpA and CpT islands, although whether 
these sequence contexts are the real substrates has yet to be determined. 
The general motifs of all DNMT enzymes have been identified in 
DNMT2, as well as the presence of the coenzyme SAM or its reduced 
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counterpart S-adenosyl-L-homocysteine (SAH), respectively. Only the 
sequence containing the TRD differs from other types of methyltransferring 
enzymes and additionally, there are no extensions in the N-terminal region.  
There are some enzymes with methyl transferase activity in bacterial 
cells as well. The DNMT2 homologues appear to resemble bacterial 
transferases, like M.Hha1 in E. coli, more than other eukaryotic methyl 
transferring enzymes. Surprisingly, DNMT2 is present in organisms with low or 
no signs of cytosine methylation, like yeast or D. melanogaster. (DONG & al., 
2001; PONGER & LI, 2005) 
3.1.3 DNMT3 
The last group of major eukaryotic methyl transferases comprises the 
DNMT3 enzymes. Apart from some special forms, the two main representatives 
are DNMT3A and DNMT3B. Both enzymes catalyze methylation of both 
hemimethylated and unmethylated DNA substrate without measurable 
differences. However, murine stem cells that cannot express the two enzymes 
are unable to methylate viral DNA after its integration into the genome. Because 
of this the DNMT3 enzymes are associated with de novo methylation. Once 
again, the basic target sites are CpG islands. In germ lines, de novo methylation 
appears to preferentially operate on repetitive sequences, like transposons or 
satellite sequences near the centromeres. (OKANO & al., 1999) 
Next to the general motifs of DNMTs, mammalian DNMT3A and 
DNMT3B possess a PWWP domain, the Zink-binding cysteine domain familiar 
from DNMT1, and several methyl group binding domains on their N-terminal 
region. (XIE & al., 1999) 
An exact functional difference between both methyltransferases has not been 
identified yet. DNMT3A is necessary for normal imprinting of the H19 and Gtl2-
Dlk1 alleles in male germ cells, but it is not associated with regular methylation 
of the Rasgrf allele. The provision of genetic imprints seems, however, not to be 
the only function of DNMT3A. A lack of this enzyme in male mouse germ cells 
leads to complete demise of these cells, which might probably not be the case, 
if there were only defects in allele-specific imprints. To date no observations 
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have been made that DNMT3A function is limited to genetic imprinting or if it 
also methylates transposons or other repetitive sequences in vivo. (KANEDA & 
al., 2004) 
DNMT3A2, a shortened isoform of DNMT3A, exists in murine 
prospermatogonia in which most de novo methylation occurs. DNMT3A2 is the 
product of alternative splicing, whereas the DNMT3A gene is transcribed from a 
promoter-like region between exon 6 and 7 and the resulting protein thus lacks 
219 amino acids. It is not known whether DNMT3A2 plays a role in setting 
allele-specific imprints or has any functional distinctions to the full-length 
enzyme. (CHEN & al., 2002) 
DNMT3B appears to be vital for normal methylation of satellite DNA. 
Loss of methylation in such sequences, especially near centromeric regions, 
leads to abnormal chromosome structures. Point mutations in the DNMT3B 
gene lead, among others, to the severe immunodeficiency – centromeric 
instability – facial abnormalities (ICF) syndrome in humans. DNMT3B-deficient 
mouse embryos suffer significant lack of satellite sequence methylation and are 
not viable. Interestingly, this is in contrast to DNMT3A-deficient mice. These 
animals show severe malformations, like microsomia and aganglionic 
megacolon, but survive the developmental period. In mouse embryos, DNMT3B 
is preferentially expressed in the trophoectoderm and later in the inner cell 
mass, where most de novo methylation occurs. Whether this enzyme plays a 
role in de novo methylation in germ cells is not known. (KONDO & al., 2000; 
LORINCZ & al., 2002) 
There is an isoform of DNMT3 which is specific for germ cells only, 
called DNMT3L. This enzyme is closely related to DNMT3A and DNMT3B, 
although it lacks the characteristic PWWP domain. Furthermore, no methyl 
transferase activity has been observed, although it is essential for regular 
methylation patterns. Evolutionary reasons might have led to the loss of a once 
existing catalytic activity. Instead more variable proteins could have evolved, as 
seen by the difference of mouse and human homologues. These new proteins 
could then serve as enhancers of the actual methyl transferring enzymes. In 
oocytes DNMT3L is associated with gene imprinting, in prospermatogonia it 
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acts in the methylation of repetitive sequences. Deficiency appears not to be 
relevant for meiosis in female germ cells, but the more in male germ cells which 
show severe abnormal cellular formations and die due to apoptosis. These 
deformations are likely consequences of desiderate transposon inactivation. 
Deficiency in both sexes show sexual dimorphism in mice and symptoms similar 
to those associated with DNMT3A deficiency. This, together with an experiment 
that DNMT3L could stimulate DNMT3A and DNMT3B activity, led to the 
conclusion that the interaction with the isoform is needed to guarantee normal 
methylation patterns in allele-specific imprints. (PRADHAN & ESTEVE, 2003; 
BOURC’HIS & BESTOR, 2004; SUETAKE & al., 2004) 
The occurrence of DNMT3 homologues in invertebrates is more 
variable than in vertebrates. Many examined species contain all three DNMT 
families, some of them only DNMT2 homologues. In whatever organisms 
DNMT1 homologues have been detected, it is expected that these organisms 
also contain at least one DNMT3 homologue. 
Plants once again show a specific version of DNMT3, the so-called 
domains rearranged methyl transferase (DRM). However, this modification has 
only been observed in flowering plants. There are some similarities, especially 
the region around the highly conserved catalytic centre. The amino acid 
sequence of the C-terminal region is 28% equal to mammalian DNMT3 
isoforms. However, DRMs together with all known plant methyl transferases do 
not contain the cysteine accumulation that is characteristic for the N-terminal 
region of DNMT1 and DNMT3 homologues. The N-terminal region contains an 
ubiquitin-associated domain which has not been observed in other methyl 
transferases and whose function is unknown. The motifs I to X are existent, 
even though the motifs VI to X are located prior to I to V. DRM homologues 
function in a mechanism called RNA directed methylation. This process appears 
to be based on the creation of short RNA sequences which recognize and 
mediate methylation of complementary DNA sequences. More homologues 
without a definite task have been identified and it is assumed that some of them 
evolved out of similar evolutionary reasons like DNMT3L in mammals. (CAO & 
al., 2000; GOLL & BESTOR, 2005) 
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3.1.4 Chromomethylases 
Chromomethylases (CMTs) are another kind of methyl transferases 
specific for flowering plants. In contrast to conventional enzymes, CMTs 
catalyse methylation of CpNpG islands. N stands for any nucleotide. A 
distinguishing property of CMTs is the existence of a chromodomain located 
between the motifs II and IV. A chromodomain is a region assumed to be an 
interface between proteins and heterochromatin. (HENIKOFF & COMAI, 1998) 
CMTs are generally associated with maintenance methylation, whereas 
de novo methylation is assumed to take place in the course of RNA directed 
methylation. (CAO & al., 2003) 
Analyses of A. thaliana revealed the three homologues CMT1, CMT2 and 
CMT3. More homologues have been identified in the genomes of other plants. 
Their exact function remains unclear and some of the encoding genes seem to 
be expendable at all. Only CMT3 in A. thaliana was shown to be involved in 
CpNpG methylation in repetitive sequences lacking CpG islands. CMT3 
knockout plants show decreased CpNpG island methylation and increased 
transposon activity, but no observable changes in the phenotype have been 
reported. The first effect is even more significant when CMT3 and MET1 are 
knocked out. (KATO & al., 2003) 
There is evidence that histone methylation is involved in CMT function 
as well. Kryptonite codes for an enzyme that catalyzes methylation of the lysine 
residue 9 in histone 3 (H3K9) and knocking out this gene results in the same 
amount of demethylation of CpNpG islands. In organisms without methylation of 
other than CpG sequences, H3K9 appears not to play a role in the regulation of 
DNA methylation. (JOHNSON & al., 2002) 
It is hypothesized that the development of this enzyme class occurred 
because of transposable gene elements with few or without CpG, but rather 
CpNpG sequences. Those transposons seem to be preferentially located in 
plants which had to devise more specific defensive mechanisms. (KATO & al., 
2003; ZILBERMANN, 2008) 
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3.2 Cytosine Demethylation 
The issue of hypermethylated DNA regions in various diseases, 
including cancer (see according chapter), as well as the general erasure of 
methylation marks in mammalian primordial germ cells raises the question of 
possible mechanisms of cytosine demethylation. Several theories on 
mammalian cytosine demethylation are available, whereas most of them are at 
least entangled in some contradictions. However, all agree with the assumption 
that DNA demethylation is on the one hand active, and on the other hand 
occurs via base excision repair. This assumption goes along with the 
hypothesized mechanism of plant cytosine demethylation which is more clearly 
elaborated than its mammalian counterpart. In this context, both the plant and 
recent mammalian models will be addressed. (JIRICNY & MENIGATTI, 2008) 
3.2.1 Base excision repair in plants 
Knockout experiments revealed two different enzyme classes that 
operate in plant cells. Demeter, expressed by the gene Medea, catalyzes 
demethylation in germ cells, whereas the repressor of silencing 1 (ROS1) and 
the Demeter-like enzymes DML2 and DML3 act in somatic cells. The 
mechanism starts with enzymatic removal of 5mC from deoxyribose, followed 
by cleavage of the phosphodiester bond by an AP endonuclease with lyase 
activity. Eventually, dCMP is inserted and the DNA strand is joined. This 
mechanism differs significantly from the proposed mammalian way of action in 
that base excision functions without the conversion of 5mC to thymine (see 
below).  
There is another striking difference between plant and mammalian 
demethylation, namely in connection with genomic imprinting. Whereas 
genomic imprinting occurs in mammals and other eukaroytes by de novo 
methylation of excessive alleles, demethylation occurs in plants for one of both 
transcriptionally inactive alleles.  
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The purpose of cytosine demethylation in germ cells refers to the 
expression of genes needed after fertilisation, whereas its counterpart in 
somatic cells appears to be a protective mechanism against hypermethylation 
by the according methyltransferases (see according chapter) in case repetitive 
sequences are located nearby. (OOI & BESTOR, 2008A) 
3.2.2 Base excision repair in mammals 
The history of suggested cytosine demethylation mechanisms in 
mammals is more distinct from that of plants.  
The first proposal included the activity of a ribozyme or ribozyme-like 
enzyme. The ribozyme theory was later abandoned. However, an RNA-
dependent enzyme was later discovered. This enzyme turned out to be a 5mC 
glycosylase and was named thymine DNA glycosylase (TDG). Its function in 
active DNA demethylation was later doubted because of its inefficiency, but it is 
still part in some theories. (JOST, 1993; CORTÁZAR & al., 2007) 
Another protein, called methyl binding domain 2 (MBD2), was 
discovered soon after the first RNA involving hypothesis. However, the 
suggested reaction with 5mC turned out to be energetically unfavourable. In 
vitro experiments with this protein turned out to be irreproducible and 
furthermore knockout experiments on mice did not reveal altered phenotypes or 
significantly different methylation patterns from control animals. A related 
protein, MBD4, however, is still part of theories on mammalian DNA 
demethylation. (BHATTACHARYA & al., 1999; JIRICNY & MENIGATTI, 2008) 
A recent experiment on Xenopus laevis (African clawed frog) oocytes 
examined the impact of growth arrest and DNA-damage-inducible protein 45 α 
(Gadd45α) on DNA demethylation. (BARRETO & al., 2007) Gadd45α is a 
protein that is located inside the cell nucleus and involved in DNA repair, 
genomic stability and suppression of cell growth. This experiment revealed that 
Gadd45α apparently causes global cytosine demethylation when overexpressed 
and global hypermethylation when knocked out. The suggested mechanism 
includes an endonuclease involved in nucleotide excision repair termed 
xeroderma pigmentosum complementation group G (XPG). However, the 
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results are being questioned and couldn’t be reproduced in a subsequent 
experiment by another group. (JIN & al., 2008) The latter results are again 
confirmed by Gadd45α-knockout experiments on mice which yielded the result 
that affected animals developed normally and were viable. Moreover no 
suspicious methylation patterns could be identified. However, other 
observations showed that Gadd45α-mutant mice suffer from chromosomal 
instability and have an increased risk of tumour development. Therefore, this 
protein may still be regarded as a crucial factor for DNA methylation. (OOI & 
BESTOR, 2008B; JIRICNY & MENIGATTI, 2008) 
The current theory of mammalian DNA demethylation basically involves 
three steps (see Fig. 4). The first one handles the oxidative deamination of 5mC 
to thymine and is currently a matter of debate concerning the involved enzymes. 
In the second step, base excision is carried out, however, by what enzymes and 
cofactors has not been clarified to date as well. The third step, though, does not 
cater for disputes any more. Similar to the plant mechanism, dCMP is inserted 
into the base vacancy and the DNA strand is therefore restored again. 
Concerning the first step, experiments provided two possibilities of 
active enzymes. The first experiments have been conducted very recently on 
genes targeted by the estrogen receptor α (ERα). The hypothesis derived from 
the results claims that the methyl transferring enzymes DNMT3A and DNMT3B 
also have demethylating capacities if SAM concentrations are low. In this case, 
the more stable enamine form (see according chapter) of cytosine or 5mC, 
respectively, after enzyme binding would destabilize the amino group at position 
C4 and increase the rate of oxidative deamination. Thus, C would be converted 
to U and 5mC to T. (KANGASPESKA & al., 2008) The main concern of this 
hypothesis is that the kinetics of SAM concentrations in vivo is too much a 
factor of insecurity to rely on experimental results out of cell nuclear conditions.  
In the other experiment, likewise conducted only very recently, 
methylated DNA fragments or plasmids were injected into Danio rerio 
(zebrafish) embryos (RAI & al., 2008). This contrary hypothesis claims that the 
deamination step is carried out by either activation-induced deaminase (AID) or 
apolipoprotein B RNA-editing catalytic component-1 (Apobec-1) or even both of 
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them. Gadd45α has been reported a cofactor for the deamination step. Here as 
well concern has been raised, especially pertaining to AID, that both enzymes 
are efficient only when their respective substrates are single stranded.  
The second step might involve either TDG or MBD4, both enzymes with 
glycosylase activity (see Fig. 4). However, the activity of TDG has already been 
asserted to be too inefficient to justify further research. Again, Gadd45α seems 
to play an enhancing role on MBD4 activity. And once again, unsteadiness for 
MBD4 has been stated. Knock-out results on mice did not produce any 
observable phenotypical degradation after birth, meaning that other factors are 
also involved in the glycosylase step. (RAI & al., 2008) 
In regard of the potentially drastic consequences of even minor 
changes in physiological methylation patterns, it may be assumed that there are 
still more factors involved in DNA demethylation that can quench the drop-out of 
one of the reported enzymes. (JIRICNY & MENIGATTI, 2008; OOI & BESTOR, 
2008B) 
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Fig. 4: Demethylation scheme 
Reaction steps of the enzymatic cytosine excision, including cofactors; for 
explanations, see text (RAI & al., 2008) 
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4 METHYL DONATORS 
4.1 SAM 
S-Adenosyl-L-Methionine (SAM) (see Fig. 5) is, among other 
biochemical pathways, the cofactor for eukaryotic methyl transferases. For 
carrying out its effect, it is located at a specific cofactor-binding domain of the 
respective methyl transferring enzyme (see according chapter). 
  SAM is synthesized by methionine adenosyl transferase which 
connects adenosyl triphosphate (ATP) to the amino acid methionine (see 
below). After the addition of the adenosyl moiety of ATP to the thiole group of 
methionine, the methyl group that is bound to the same thiole group becomes 
chemically more reactive and can serve as the donor methyl group for various 
substrates including cytosine. 
After delivering the methyl group to the according substrate, the 
resulting product S-adenosyl-L-homocysteine (SAH) is hydrolysed by S-
adenosyl homocysteine hydrolase. Homocysteine is again oxidized to 
methionine by homocysteine methyl transferase and various methyl donators. 
Together with ATP SAM is regenerated. (ELMADFA & LEITZMANN, 2004) 
 
 
Fig. 5: SAM 
Chemical structure of S-Adenosyl-L-Methionine (SAM) 
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4.2 Methionine  
Methionine (see Fig. 6) is one of eight essential amino acids, meaning 
the human organism cannot synthesize it by himself and has to take it up via 
nutrition. Considerable amounts are found in meat and fish, eggs, plant seeds, 
some nuts and grain products. It contains a thiol group at position 5 with a 
methyl group instead of an H atom. The transferability of this methyl group 
makes methionine an important cofactor in various methylation processes.  
Methionine can be synthesized only by plants and microorganisms. In 
various steps, aspartate is converted to homoserine to which succinate is 
added. Then succinate is removed and exchanged by cysteine, forming 
cystathionine. The latter is converted to homocysteine. Eventually, a methyl 
group from e. g. methyl tetrahydrofolate (MTHF) (see below) or cobalamin (see 
below), respectively, is transferred to homocysteine, completing the 
biosynthesis of methionine. Mammals and other animals are capable only of the 
last step. 
Methionine deficiency leads to fatty liver in rats and other symptoms. 
(ELMADFA & LEITZMANN, 2004) 
 
 
Fig. 6: Methionine 
Chemical structure of L-Methionine 
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4.3 Folic acid  
Folate is a vitamin and essential cofactor in biochemical processes that 
require the transfer of methyl groups. Considerable amounts of folate are 
commonly found in green vegetables, some fruits, yeast, liver, kidneys and 
eggs. Intestinal microorganisms contribute to the folate supply in humans to a 
certain degree. 
The correct name is pteroyl mono- or polyglutamate. Folate consists of 
a pteridine ring, a p-amino-benzoic acid ring and one or up to eight glutamate 
moieties. The biologically active form is tetrahydrofolate (THF), whereas the 
positions 5, 6, 7 and 8 contain an H-atom and the double bonds between these 
positions are resolved (see Fig. 7). The enzymes capable of this reduction are 
7,8-dihydrofolate reductase and 5,6,7,8-tetrahydrofolate reductase. A one-
carbon group can be added to the positions 5 and 10 by 5,10-MTHF synthase, 
forming 5,10-methylene tetrahydrofolate (5,10-MTHF). The methylene group 
can be reduced to a methyl group on position 5 by 5,10-MTHF reductase, 
whereas the result is 5-methyl tetrahydrofolate (5-MTHF). Both, 5,10-MTHF and 
5-MTHF, can serve as methyl donators for various biochemical pathways, 
including methionine and SAM regeneration (see above). Methyl donators for 
‘activating’ one-carbon THF are serine, glycine, histidine and formiate. 
Lack of folate leads to elevated homocysteine levels, indicating that it is 
associated with methionine regeneration. Moreover, since THF is involved in 
purine and DNA synthesis, cell division is slowed down. The consequence 
becomes visible by anemia, because erythrocytes are among the cell types with 
the fastest reproduction rate. Other deficiency symptoms include general signs 
of exhaustion, depression, behavioral disorders and especially neural tube 
defects in case of deficiency during pregnancy. In other fast replicating tissues, 
e. g. intestinal tissues, lack of folate seems to be involved in tumourigenesis as 
well. (ELMADFA & LEITZMANN, 2004; BOLLHEIMER & al., 2005) 
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Fig. 7: Folate 
Chemical structure of non-hydrated folate with the designated positions 
for hydrogenation (HART & al., 2006) 
4.4 Cobalamin  
The second vitamin playing a noteworthy role in methyl metabolism is 
vitamin B12 or cobalamin (see Fig. 8). Cobalamin is a macromolecule with 
several chemical functions. The striking structure element is a corrin-ring with a 
covalently bound cobalt ion in the centre. This cobalt ion additionally connects 
the 5,6-dimethylbenzimidazol-ribonucleotide to the corrin ring and also binds the 
functionally characteristic moiety. Among others, this can be a methyl group or 
a 5’-deoxyadenosyl group, both providing co-enzyme function in the human 
organism. 
Cobalamin can be synthesized only by microorganisms. Hence, 
nutritional sources are mostly yeast, eggs, meat and dairy products. 
 5’-deoxyadenosyl-cobalamin plays a role in the degradation of odd-
numbered fatty acids and some amino acids by serving as a co-enzyme for 
methylmalonyl CoA-mutase. Methyl-cobalamin is the physiological methyl 
donator for the regeneration of methionine by methionine synthase. The 
connection with THF is that the methyl group from 5-MTHF is transferred to 
cobalamin, providing cobalamin with its methyl donating function and, on the 
other hand, empowering THF to travel across cell membranes. 
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Lack of cobalamin, due to low nutritional amounts or intestinal 
malabsorption, leads to elevated homocysteine levels, megaloblastose and 
anemia, degeneration of several regions of the spinal cord and other general 
symptoms. The consequences of deficiency are rather similar to those of folate 
deficiency, since the methyl donating function of cobalamin affects rapidly 
replicating cells as well. (ELMADFA & LEITZMANN, 2004) 
 
 
Fig. 8: Cobalamin 
Chemical structure of Vitamin B12 / Cobalamin 
4.5 Choline  
Another notable methyl donator in human nutrition is choline, or N,N,N-
trimethyl ethanolamine, respectively (see Fig. 10). The main biological functions 
next to providing methyl groups are the formation of phospholipids for increased 
cell membrane flexibility and the synthesis of the neurotransmitter acetylcholine. 
Although choline has once been classified as a B-vitamin, it is no longer 
regarded as an essential nutrient, because it can be synthesized by 
decarboxylation of serine. Among the foods containing considerable amounts of 
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choline are liver, meat, peanuts, whole grain products, potatoes, coffee and 
some fruits and vegetables.  
Choline itself does not serve as a methyl donator. It rather has to be 
oxidized to betaine, or N,N,N-trimethyl glycine, respectively, by the mitochondria 
of liver and kidney cells. The enzyme betaine-homocysteine-methyltransferase 
constitutes an alternative pathway for methionine regeneration next to MTHF 
(see above). 
To date no well-defined symptoms for choline deficiency have been 
described, however, evidence suggests that it might lead to growth arrest, 
infertility, disruption of liver function, muscle weakness and probably even 
cancer due to aberrations in DNA methylation in animals. Potential symptoms in 
humans range from neural tube defects to fatty liver, hepatosteatosis and 
muscle cell damage. (ELMADFA & LEITZMANN, 2004; ZEISEL, 2008) 
 
 
Fig. 9: Choline 
Chemical structure of N,N,N-trimethyl ethanolamine / choline  
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5 COMPLEX PHENOMENA FEATURING 
CYTOSINE METHYLATION 
5.1 Genomic imprinting 
Genomic imprinting is a phenomenon that involves DNA methylation. 
Hereby one allele of a gene is subject to shutdown, whereas the other allele is 
regularly expressed. For most genes both alleles are expressed. However, in 
some cases there needs to be an expression of either the maternal or the 
paternal allele to warrant normal cell metabolism. Recent estimations for 
mammalian genes go up to 600 genes susceptible to imprinting of which more 
than 80 have been identified so far and of which about one third are shared by 
humans and mice. (LUEDI & al., 2005) Those genes are functionally haploid, 
because only one copy can be expressed in a cell. The pattern of gene 
imprinting varies between species, but also between different tissues of the 
same organism. Thus, imprinting plays a role in adult tissue metabolism and 
embryonic development, as well as in certain diseases like cancer and inborn 
disorders. The latter cases are characterized by an abnormal expression 
pattern of a specific gene due to imprinting of both alleles or loss of imprinting 
(LOI) on both alleles. (DOLINOY & al., 2007; KINOSHITA & al., 2008) 
The first hypothesis for gene imprinting was created in the 1980s after 
the observation that diploid cells derived from two male and two female 
pronuclei, respectively, had not shown regular growth. (BARTON & al., 1984) 
One theory behind the function of gene imprinting claims that there is 
an evolutionary reason. That is the growth control of embryonic tissue. (HAIG & 
GRAHAM, 1991) This theory is based on the imprint status of two genes. The 
first is the gene encoding IGF-2, the other is the gene encoding the receptor for 
mannose-6-phosphate (M6P) and IGF-2. IGF-2 is an essential growth factor for 
embryonic development, but it is also produced in adult tissues. Normally, the 
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expression is monoallelic, with the exception of the adult liver, where expression 
is biallelic. The receptor binds both M6P and IGF-2, but is not located on the 
cell surface, but rather on the surface of cellular compartments for degradation 
of proteins. M6P/IGF-2 binds and transports IGF-2 and phosphomannosylated 
glycoproteins to the lysosomes, where they are dismantled. The IGF-2 gene is 
imprinted and thus repressed on the maternal allele, whereas in connection with 
the M6P/IGF-2R gene the paternal allele is affected by imprinting. These 
observations support the idea that the paternal alleles of a gene are responsible 
for growth and the maternal alleles seek to suppress or control growth. This 
status is typical for humans and remains in most tissues, except for the liver 
whose cells express the IGF-2 gene on both alleles. In contrast, rats and mice 
express both alleles in most tissues. Interestingly, in many experimental and 
human tumour cells the IGF-2 gene is overexpressed because of LOI. This 
overexpression might be one explanation for the uncontrolled growth of tumour 
cells and for the higher susceptibility of rodents to cancer in comparison to 
humans. (BARLOW & al., 1991; JIRTLE, 1999) 
Another theory suggests that imprinting protects a cell from noxious 
DNA sequences, like transposons or viral DNA. (SUZUKI & al., 2007) 
5.1.1 Molecular control of genomic imprinting 
The exact molecular mechanisms are not known to date. One important 
observation, however, is the dissimilar handling of imprinted genes in male and 
female gametes. During gametogenesis, or more exactly during the 
development of primordial germ cells, DNA methylation marks are erased in 
both sexes, but in female gametes these deletions are reversed, though this 
seems not to be the case in male gametes. The point of a new establishment of 
imprinting marks is not exactly known, although evidence suggests that it 
occurs after the fusion of male and female gametes during the early phases of 
embryonal development. (PULFORD & al., 1999) 
In male primordial germ cells, some exceptions have been highlighted. 
It is known that next to several repetitive sequences, like the intracisternal A 
particle (IAP), imprinted genes are not affected. The protein Stella which is 
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expressed at high levels in primordial germ cells appears to somehow protect 
methylated CpG islands from active demethylation (see according chapter). It is 
hypothesized that Stella is transported to the according methylated regions and 
protects them from the demethylation machinery. After fertilisation the marks of 
imprinting can be undone, depending on the type of cell. At this stage as well, 
Stella play a role in protecting methylated CpG islands from losing their 
methylation marks. (NAKAMURA & al., 2007) 
Imprinted genes usually appear in clusters that are regulated by 
imprinting control regions (ICR). (VERONA & al., 2003) The activity of ICRs 
themselves is regulated by DNA and histone modifications. Mutations and 
aberrant methylation can lead to LOI of genes within the cluster. The result that 
eventually leads to disease is either the loss of gene expression on one of the 
alleles or biallelic, therefore causing overexpression of genes that code for 
growth factors or oncogenes.  
This model can be exemplified by the H19/IGF-2 cluster 
(THORVALDSEN & al., 1998) which contains an ICR between the two genes 
(see Fig. 10). The function of IGF-2 has been mentioned above and the function 
of H19 is the expression of non coding RNA with oncogenic attributes. Both 
genes are important during embryonic development and are downregulated in 
differentiated tissues. The DNA sequence of the cluster is different between 
human and mouse which most of the experimental data are derived from, but 
the functionality is rather similar, thus it is transferred from mouse models to 
human. At the 5’ end of the cluster, following H19, resides an enhancer region 
which interacts with the promotor of either gene, depending on the methylation 
status of the ICR. Normally the ICR of the allele delivered by the male germ cell 
is methylated causing the enhancer region to interact with the IGF-2 promoter. 
In contrast, the ICR of the allele from the female germ cell is unmethylated and 
here the enhancer region interacts with the H19 promoter. Experimental data 
showed that an insulator called CCCTC-binding factor (CTCF) can bind to the 
unmethylated ICR. An insulator is a protein that binds to functional DNA 
sequences or also to chromatin proteins and therefore inhibits their capacities. 
A remarkable difference between the mouse and human ICR of this cluster is 
Chapter 5 - Complex Phenomena Featuring Cytosine Methylation 
the number of CTCF-binding sites. While the mouse ICR contains four such 
sites, seven have been identified in the human ICR. (IDERABDULLAH & al., 
2008) The consequences of deletions within the human ICR are explained 
below. 
 
 
Fig. 10: H19/IGF-2 imprinting 
Schematic overview on the impact of different methylation states in the ICR of 
the H19/IGF-2 cluster; for explanations, see text (IDEERABDULLAH & al., 
2008) 
5.1.2 Consequences of aberrant imprints  
The molecular mechanisms of these events have, however, not been 
exactly clarified. On the paternal allele there appears to be physical interaction 
between the enhancer and the IGF-2 promoter. It is assumed that on the 
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maternal allele there is some change of chromosomal conformation as well, but 
experimental data are contradicting. Next to several types of tumours two inborn 
diseases are related to genetic or epigenetic irregularities of the H19/IGF-2 
cluster. These are the Beckwith-Wiedemann-Syndrome (BWS) and the Silver-
Russel-Syndrome (SRS). BWS includes several severe birth defects and 
affected children have an increased risk of childhood cancer. SRS is a dwarfism 
growth disorder with a number of additional conditions. Because of the 
mentioned oncogenic features of the H19 transcript and the function as a 
growth factor of IGF-2 it seems reasonable that defective imprinting of the 
cluster leads to either undergrowth in case of loss of expression or overgrowth 
disorders in case of biallelic overexpression. The exact mechanisms have not 
been identified yet. However, LOI caused by microdeletions or aberrant 
methylation of the ICR seems to be involved. The ICR of BWS patients is 
hypermethylated, whereas the one of SRS patients is hypomethylated, both 
leading to LOI on the cluster and pathologic gene expression. Aberrant 
methylation can occur due to microdeletions inside the ICR sequence that affect 
the CTCF binding sites, as shown in BWS patients. However, not all such 
deletions implicitly lead to the disease. For example a larger deletion which 
eliminates the binding sites 3 to 5 does not lead to aberrant methylation on the 
maternal allele. The reason for this is not known, but there are two possible 
explanations. One is that the deletion leads to an ICR sequence similar to the 
full-length version, the other states that unidentified regulatory factors play a 
role which would be affected by shorter deletions. (KANDURI & al., 2002; 
BLIEK & al., 2006; CERRATO & al., 2008) 
A disease that is strongly related to the imprint status of genes is 
cancer. In this case LOI is generally related to either expression of 
physiologically silent alleles of imprinted growth factor genes or oncogenes or 
silencing of physiologically active alleles of imprinted tumour suppressor genes. 
IGF-2 appears to play a role here as well. Wilm’s tumour for example is a 
kidney tumour that affects children who suffer from BWS caused by errors in the 
H19/IGF-2 cluster. A biallelic expression of IGF-2 is stated to be responsible for 
the typically enlarged kidneys of the patients and the tumour. Other types of 
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cancer related to IGF-2 overexpression are lung cancer, breast cancer, ovarian 
cancer and glioma. However, not only IGF-2 overexpression, but also M6P/IGF-
2R underexpression is likely to play a role in cancer. In several tumours this 
receptor gene was downregulated by abnormal imprinting status, which likely 
amplifies the effect of IGF-2 overexpression. (KANEDA & FEINBERG, 2005; 
IDERABDULLAH & al., 2008) 
LOI in the DLK1/GTL2 gene is related to Wilm’s tumour as well. Other 
genes for which LOI is involved in cancer development are ARHI and PEG1 and 
more are expected to be identified by upcoming research. (FEINBERG, 2007) 
5.2 Metastable epialleles 
The term of metastable epialleles describes a phenomenon similar to 
genomic imprinting, yet in some aspects different enough to be called a 
condition on its own. Metastable epialleles are a property of mammalian 
genetics and constitute a remarkable link between nutrition and other 
environmental influences to gene expression. While the epiallele by itself 
describes an allele that can exist in a different methylation state than its 
counterpart and therefore should be categorized within genomic imprinting (see 
according chapter), a metastable epiallele is more flexible in its methylation 
state. (RAKYAN & al., 2002) Whether it is silenced by hypermethylation or 
normally expressed is determined either by chance or by the provision of methyl 
donating nutrients, e. g. folic acid or choline, or hormones, e. g. genisteine, 
during embryonal growth and early development. Either way, mitotic inheritance 
is generally given. Furthermore, some of the best known metastable epialleles 
are considered ‘infected’ with transposable DNA elements, mostly IAP, but also 
L1. (DOLINOY & al., 2007) 
Different methylation states of metastable epialleles lead to extensively 
or partly altered phenotypes in genetically identical organisms. This latter 
phenotypical occurrence is referred to as mosaicism or variegation and can 
express itself in e. g. mottled coat colour or kinked tails in mice. However, a 
difference has to be made from the term position effect variegation (PEV). This 
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phenomenon is not limited to mammals and was first discovered in D. 
melanogaster and A. thaliana. It describes the phenotypical effects that occur 
when normally active genes are translocated near heterochromatic regions and 
thus silenced. Heterochromatin means a rather tightly packed series of 
nucleosomes (see introduction) whose DNA sequence is physically silenced by 
its inaccessibility for the transcription machinery. PEV can also affect a 
complete organism or embody itself as mosaicism. (GREWAL & ELGIN, 2002) 
Another difference has to be made from genomic imprinting (see 
accoding chapter). While in the latter case it is determined whether the 
maternally or the paternally inherited allele is silenced, the consequences of the 
methylation state of a metastable allele is not dependent on the parental origin. 
Moreover, both alleles might be affected by silencing via CpG island 
methylation without immediately making development unfeasible. It should be 
mentioned as well that, as noted, genomic imprinting marks are set during 
gametogenesis and fertilisation, whereas metastable epialleles appear to be 
created during early embryonal growth. (WEICHMAN & CHAILLET, 1997; 
SUTHERLAND & al., 2000) 
The question which allele is dominating can by now not be answered 
uniformly. Since the methylation state can repress an otherwise dominant allele 
and therefore excludes the assumption of the traditional dominant-recessive 
classification, the term ‘semi-dominant’ seems appropriate, yet should not be 
taken too literally. (RAKYAN & al., 2002) As follows, some examples of genes 
with metastable epialleles are described. 
5.2.1 Avy epiallele  
Probably the most popular metastable epiallele is the murine Agouti 
gene. Its name refers to the coat colour of the wild type rodent species agouti 
which is light to dark brown. A variant of this gene is also found in mice. 
Laboratory mice with yellow fur-colour combined with a high incidence of 
overweight, insuline resistance and tumour development compared to control 
animals have been observed. It was later found out that a mutation in the Agouti 
gene was responsible for the altered phenotype and disease susceptibility and 
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therefore the altered gene was termed Agouti viable yellow gene (Avy). Notably, 
one allele or both can be affected. (MORGAN & al., 1999) 
The normal variant in mice encodes an endocrine signal protein that 
causes melanocytes to produce the pigment protein eumelanin. This pigment is 
responsible for black to brown skin, hair and fur colour. In contrast, the altered 
variant in mice encodes a different protein commanding melanocytes to 
synthesize phaeomelanin, a different pigment protein which causes blonde to 
yellow colour and pigmentation. Furthermore, this gene variant leads to the 
noted physiological disadvantages in some way. (DUHL & al., 1994) 
The noteworthy aspect at this point is that Avy contains an IAP 
transposon insertion next to its upstream transcription start site. A cryptic 
promoter inside the IAP insertion leads to the expression of an altered protein 
und eventually to different fur colour in mice. (MILTENBERGER & al., 1997; 
MORGAN & al., 1999) An animal homozygous for the unchanged A allele 
exhibits a regular phenotype, whereas Avy is the dominant allele, thus 
heterozygous animals show the yellow coloured phenotype (see Fig. 11). 
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Fig. 11: Methylation states of the Avy allele 
Schematic overview of phenotypical traits of Avy mice depending on the 
methylation state of the affected allele; for explanations, see text (RAKYAN & 
al., 2002) 
 
However, the issue is not handled with that yet. As noted, transposable 
elements belong to the group of DNA sequences that are subject to repression 
by pronounced CpG island methylation. In vivo feeding studies and genetic 
examinations on Agouti-mice revealed interesting results on the offspring. 
Pregnant animals were fed with diets containing different amounts of methyl 
group donators (see according chapter), which lead to corresponding results 
visible at the offspring. High dosages of nutritional methyl donators or 
methylation-inducing hormones led to a phenotype which was superficially not 
distinguishable from wild type mice. Moreover, the described physiological 
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disadvantages fell away. These offspring were therefore termed ‘pseudoagouti’ 
(see Fig. 12). Lower dosages led to mottled fur colour. Concurrently, it was 
found out that CpG island methylation of the IAP insertion was responsible for 
the altered condition. Moreover, it was shown that mice homozygous for the Avy 
allele exhibited the regular yellow phenotype when one allele was methylated. 
Contrary, if both alleles were methylated, the animals would exhibit the 
pseudoagouti phenotype (see Fig. 11). Interestingly, methylation of the noxious 
sequence seems to shut down the gene, leading to the expression of the A 
allele in heterozygous animals. (MORGAN & al., 1999; DAY & al., 2002; NAAZ 
& al., 2003) 
 
 
Fig. 12: Avy and  ‘pseudoagouti’ mice 
Results of feeding experiments demonstrate that the left mouse shows the 
characteristic yellow-coloured phenotype based on the Avy allele, whereas the 
‘pseudoagouti’ offspring lost these traits due to high methylation of this allele; 
for explanations see text (DOLINOY & al., 2007) 
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A definite milestone in epigenetic research was an observation made in 
connection with metastable epialleles and especially with the Avy variant. The 
distinct methylation patterns are inherited transgenerationally, i. e. pseudoagouti 
mothers deliver the same phenotypical traits to their offspring. The reason, like 
in conjunction with the phenomenon of genomic imprinting (see according 
chapter), was stated to be ineffective demethylation during the formation of 
gametes. Therefore, it was hypothesized that changes in the methylation 
pattern that an organism had obtained in early development could affect not 
only its own gene expression, but also that of its progeny. (RAKYAN & BECK, 
2006) 
5.2.2 AxinFu epiallele 
Another known gene with metastable epialleles is the murine Axin gene 
and its epigenetic variation AxinFu. The latter is again originated in the insertion 
of an IAP sequence, however, in contrast to the Avy allele this insertion is not 
located near the promoter, but within intron 6 of the original gene. Thus, the 
cryptic promoter induces the creation of an abbreviated protein with lower or 
without proper function. Axin encodes a protein that inhibits the WnT pathway. 
This latter biochemical network is indispensable for embryonal growth. Targeted 
inhibition causes embryonal tissue to develop axes, therefore the name Axin. 
The decrease of function associated with the AxinFu mutation brings about kinks 
in the tails of affected mice. Observations concerning the methylation status of 
the insertion revealed similar results as with the Avy allele. A high degree of 
CpG island methylation leads to a more wild type-resembling phenotype and 
the metastability can be meiotically inherited. (VASICEK & al., 2004; 
WATERLAND & al., 2006) 
5.2.3 CabpIAP epiallele  
A bioinformatics approach recently yielded another IAP insertion in a 
gene that would be specific for the mouse strain C57BL/6J . This gene codes 
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for the CDK5 activator binding protein (Cabp). The mutated gene was termed 
CabpIAP.  The specialty of this case is that instead of one functional transcript of 
about 2 kB, a number of shorter transcripts are created. Starting from the 
original promoter at the 5’ end, the non-functional transcripts are terminated 
shortly before the cryptic promoter of the IAP sequence. Beginning from the 5’ 
end of the new promoter, another RNA sequence is transcribed. Thus the 
CabpIAP allele is the first with an upstream and downstream impact on gene 
transcription. (DRUKER & al., 2004) 
5.2.4 Other epialleles  
Other murine genes with metastable epialleles are known, e. g. Axial 
defects and Disorganisation. Mutations in the first cause neural tube defects 
and mutations of the latter bring forward skeletal abnormalities. However, it is 
not known if the mutations are based on the insertion of transposable elements. 
Genes like BLG, RSVIgmyc, or genes from the lac operon that have been 
transgenetically introduced into mice strains have metastable properties too. 
The reason is suggested to be a protective mechanism against DNA sequences 
that have been recognized as foreign, as is the case with repetitive sequences 
and transposable elements. However, variegation effects have not been closely 
examined for some of the above mentioned genes, nor has the question of 
mutation by insertion of transposable elements been answered. (RAKYAN & al., 
2002) 
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6 COMPLEX DISEASES ASSOCIATED WITH 
CYTOSINE METHYLATION – CANCER 
6.1 General aspects 
 Cancer is a complex disease and has its origins in a variety of causes 
and at least as many influencing factors. In industrialized countries cancer is 
ranked among the most prominent causes of death next to coronary heart 
diseases and diabetes. Some of the main factors influencing cancer are 
nutrition, environment, genetic background, age, sex and disease history. 
However, within these deeply intertwined factors, epigenetic phenomena have 
been hypothesized to play an essential role in development and progression of 
this disease.  
 Among epigenetic changes in cancerous diseases, irregular DNA 
methylation was the first to be discovered. (FEINBERG & VOGELSTEIN, 1983) 
The pattern of methylated CpG islands frequently differs significantly in tumour 
cells in comparison to somatic cells (see Fig. 13). However, tumour cells of one 
single type are characterized by both, hypo- and hypermethylation. This 
apparent contradiction is resolved by the methylation status of different DNA 
sequences. Then, the different tumour types also show distinct methylation 
patterns relative to each other. While the genomes of tumours of the 
gastrointestinal tract are the most hypermethylated, the genomes of sarcomas 
and ovarian cancers exhibit the least hypermethylation. These findings are in 
contrast to a former hypothesis that cancer is solely a genetic disease. 
However, in the course of transcriptome-wide analyses it was shown that CpG 
island hypermethylation within gene promoters occur in around 5 percent of 
genes in individual tumours. This appears to be a far more drastic change in the 
metabolism of an affected cell than mutations in the DNA sequence. In general, 
gene sequencing of tumour genomes revealed fewer mutations than would 
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have been expected by systematic surveys. Moreover, comparative analyses of 
malignant glioma genomes showed that pathological CpG island methylation 
patterns play a more important role for tumour development than sequence 
mutations. Another fact that plays a role in this regard is that most known 
carcinogens are not genotoxic. These and other recent observations keenly 
point out that research on the origin of cancer and on ways of treatment cannot 
neglect the factors that influence the way of gene expression above the pure 
nucleotide sequence, i. e. epigenetic factors. (JONES & BAYLIN, 2002; HIRST 
& MARRA, 2008) 
 
 
Fig. 13: Epigenetic alterations in cancer 
Scheme of epigenetic alterations in cancer cells and consequences for genomic 
activity and stability (HIRST & MARRA, 2008) 
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Hypomethylation generally affects the CpG islands in promoters of 
genes that encode growth factors. Such genes are termed ‘oncogenes’ because 
of their growth promoting function that favours tumour cell proliferation when out 
of physiological control. A prominent example is the IGF-2 gene which might 
suffer loss of imprinting on the maternal allele (see according chapter) and 
therefore encourage uncontrolled cell growth. (JIRTLE, 1999) Other genes that 
function as oncogenes in a hypomethylated state are HRAS in gastric cancer, 
the genes coding for carbonic anhydrase IV in renal cell cancer and for a 
calcium-binding protein in colon cancer. The MAGE gene family is part of a 
group referred to as cancer/testis (C/T) antigens. These genes are expressed 
normally in the testicles, but in a hypomethylated state they are also expressed 
in cancer cells. (WILSON & al., 2007) 
Moreover, CpG island hypomethylation affects intragenic and, more 
importantly, extragenic repetitive regions, like transposable sequences and 
satellite repeats. No data is available on the interaction between the activation 
of transposons and tumour cell growth, but it is assumed that moving DNA 
segments disrupt chromosomal stability. The same may be true for the loss of 
satellite repeat repression, causing in some way breakage points on a 
chromosome, especially at the pericentromeric region. (QU & al., 1999) Other 
parasitic sequences than transposons are directly responsible for certain 
cancerous diseases. For example, the genome of the HP virus which causes 
cervical cancer becomes gradually hypomethylated in the course of the 
disease. (KIM & al., 1994) 
On the other hand, hypermethylation in tumour cells generally affect the 
promoters of tumour suppressor genes. Common to these genes is their 
regulatory function for a physiological cell existence in common. They code for 
several kinds of receptors, cell cycle control proteins, apoptosis inducing 
proteins, DNA repair enzymes, enzymes with antioxidative function, but also 
DNA mismatch repair enzymes. Examples are MGMT, GSTP-1, CDH-1, 
CDKN2A, CDKN2B, APC, VHL, and hMLH-1. (ESTELLER, 2000) 
Hypermethylation has also been correlated to enhanced gene expression in 
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tumour cells, albeit not in promoter regions, but in intragenic regions. Exon 5 in 
the gene PAX6 serves as an example for colon and bladder cancer. (SALEM & 
al., 2000) 
In addition, hypermethylation affects DNA sequences coding for 
noncoding micro-RNA (miRNA). While some miRNAs are ascribed oncogenic 
functions, most seem to be involved in negative regulation of gene expression. 
A prominent example is the let-7 family. This group of miRNAs downregulates 
the expression of ras genes and HMGA-2 which are known as oncogenes. 
(GUIL & ESTELLER, 2009) 
Resuming, it can be said that both hypo- and hypermethylation can lead 
to either activation or silencing of cancer-related genes. However, current data 
advises not to overestimate the extent of CpG island hypermethylation. 
(FEINBERG & al., 2006) 
6.2 The role of stem cells 
A striking hypothesis concerning tumour development links uncontrolled 
growth not to somatic cells, but rather to stem cells. It is stated that stem or 
progenitor cells located in a specific tissue transform to pre-tumour cells due to 
epigenetic changes. Such cells have been found in normal tissues of cancer 
patients. An example for the relevance of DNA methylation in this context is 
provided by the gene p16ink4A. The exact function of this gene has not been 
clarified, however, its methylation-induced silencing prolongs the life of stem 
cells and might potentiate possible negative effects for tumour cell formation. 
Moreover, the protein encoded by the SFRPs gene is an antagonist to the Wnt 
pathway and SFRPs silencing causes Wnt to be overexpressed in stem cell 
populations of colorectal carcinoma samples. Together with the rather early 
nature of epigenetic changes, these observations support the progenitor theory. 
Cytosine methylation is not the only alteration made responsible for tumour 
development, lysine methylation of histone 3 (H3K4, H3K27) seems to play a 
role as well.  
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Concerning aberrant methylation, three example genes should be 
noted. These are IGF-2, MLL-1 and the genes that encode the polycomb group 
proteins. Loss of imprinting (see according chapter) of IGF-2 leads to an 
enlarged accumulation of intestinal progenitor cells and increased activity of 
progenitor cell-related markers in Apc-mutated mice before tumour 
development. The same observation has been made in humans. The other two 
genes are crucial regulators in stem cells, responsible for keeping the 
undifferentiated state of these cells. In tumour cells, these genes are reactivated 
and overexpressed, further strengthening the role of stem cells in cancer 
development.  
Finally, nuclei of tumour cells, e. g. melanoma or medulloblastoma that 
have been inserted into oocytes were able to develop to blastocyst stage and 
even viable mice. (TSAI, 2004; FEINBERG, 2007) 
These findings strongly indicate that epigenetic alterations in stem and 
progenitor cells are the origin in the development of cancerous diseases or at 
least play an important role. 
6.3 Epigenetic biomarkers for cancer diagnosis  
Associative markers for cancer detection include the lower methylation 
state of peripheral blood cells in connection with bladder cancer. The 
associated risk is classified as high and samples are rather easy to obtain. 
Epigenetic changes also seem to be involved in the H. pylori mediated 
mechanisms that cause gastric cancer in infected individuals. (TAHARA, 2004) 
A rather novel approach for cancer diagnosis comprises the 
examination of the methylation status of certain genes. E. g. hypermethylation 
of MGMT or p16ink4A can be observed up to three years prior to the diagnosis 
of squamous cell lung carcinoma. GSTP-1 hypermethylation is a suitable 
marker for the diagnosis of prostate cancer, because it occurs in up to 90 
percent of patients. Other genes or their methylation status, respectively, like 
THBS-1, SFRP-1 and some cadherin genes provide information about survival 
chances. 
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The administration of appropriate medication (see below) should lead to 
demethylation of cytosine residues. This effect can, among others, be observed 
by the activity of O(6)-methylguanine-DNA methyltransferase (MGMT). This 
enzyme restores guanine after alkylation. Its increased sensitivity towards 
alkylating agents is a sign of increased expression due to demethylation at the 
gene’s promoter. Other markers for the success of a therapy include the activity 
of the base mismatch repair enzyme hMLH-1 and GSTP-1, as well as the 
methylation status of BRCA-1, a gene related to familial breast cancer. 
(MULERO-NAVARRO & ESTELLER, 2008; ZHU & al., 2008) 
6.4 Epigenetic drugs for cancer treatment 
Candidate drugs (see Fig. 14) for the treatment of cancer on the level of 
cytosine methylation can be divided into two classes. The first comprises 
cytidine analogues, the other consists of various biomolecules most of which 
are in use for several clinical applications. Experiments credited inhibitory 
effects on cytosine methylation to the latter group. All drugs are hypothesized to 
interfere with DNMT enzymes and thus inhibit hypermethylation and silencing of 
anti-proliferative genes (see above).  
Two cytidine analogues are 5-aza-cytidine (5-aza-CR) and 5-aza-2’-
deoxy-cytidine (5-aza-CdR or decitabine, respectively). Neither chemical is 
stable in aqueous solution or well bioavailable and especially 5-aza-CR is 
toxicologically not impeccable. These drugs have already been approved and in 
addition, three more cytidine analogues are currently being tested against 
haematological malignancies. These are dihydro-5-azacytidine (DHAC), 5-
fluoro-2’-deoxy-cytidine (FCdR) and zebularine. These analogues are more 
stable in aqueous solution and show less toxic properties. All mentioned drugs 
have in common that they are incorporated into the DNA instead of regular 
cytosine and form a covalent and stable complex with the methyl transferring 
enzyme. After the methyl transfer to the C5 position of the incorporated 
analogue, the remaining proton cannot slide to the C6 position (see according 
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chapter). The thiol group of the enzyme remains bound to the C6 position and 
therefore the enzyme cannot be released.  
Potential non-analogue drugs are procaine and procainamide, 
hydralazine, (-)-epigallocatechin-3-gallate (EGCG) and RG108. Procaine and 
procainamide, an anesthetic and anti-arrhythmic drug, respectively, are 
hypothesized to bind sequences with high CpG island occurrence and thus 
prohibit methyl transferring enzymes from binding to the cytosine position to be 
methylated. Hydralazine, intended as an anti-hypertensive drug, and EGCG, a 
herbal phenolic compound, have also shown inhibitory effects on DNA 
methylation. RG108 is a promising candidate because of its specificity towards 
the catalytic centre of DNMT1, especially in regard to hypermethylated tumour 
suppressor genes. Furthermore it shows little toxicity. However, the major 
drawback is the low solubility in aqueous solution and therefore a drastically 
limited applicability. (JAIN & al., 2008; MAI & ALTUCCI, 2008) 
 
 
Fig. 14: DNMT inhibitors 
 Overview on the chemical structure of various drugs that inhibit cytosine 
methylation (MAI & ALTUCCI, 2008) 
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6.5 Cause or consequence 
In this regard, the question whether epigenetic changes are cause or 
consequence of cancer development should be addressed. In the context of 
LOI, exemplified by that of IGF-2, the question seems plain to answer. The 
erroneous modification exists from early development onwards and an 
extremely increased risk of embryonal and childhood tumours in connection 
with BWS are the consequences. LOI of this gene also occurs in adults at a 
frequency of 5-10 percent and correlates with a fivefold increased risk of 
developing colorectal benignant and malignant neoplasms. Together with an 
associated family history of colon carcinomas that indicates heritability of this 
disease, these findings seem to confirm the causality of cytosine methylation for 
the development of cancerous diseases. 
The answer to this question seems, however, not that simple. One 
problem is that neither mutations, nor aberrant methylation patterns have yet 
been identified for genes directly responsible for cytosine methylation. Diseases 
like the Rett- or the ICF-syndrome for which mutations occur in the MeCP2 
protein (see according chapter) and DNMT3B (see according chapter), 
respectively, are not associated with an increased risk of cancer. Moreover, the 
use of 5-aza-CdR did not provide continuously stable results, indicating that 
epigenetic errors could be an effect, but not necessarily a cause, as the 
development of a tumour progresses.  
Other evidence again argues for a causal relation. Next to LOI of IGF-2, 
it has been shown in breast cancer patients that the gene p16 becomes 
gradually hypermethylated along with age in both, normal and cancerous 
tissues. Additionally, the development of T-cell lymphomas appears to be a 
consequence of chromosomal instability due to hypomethylation of repetitive 
satellite sequences.  
Mice experiments further strengthen the causal role of methylation. 
When DNMT1-knockout mice are crossed with Apc-mutated multiple-intestinal-
neoplasia (MIN) mice, the result is a higher frequency of intestinal and liver 
tumours and interestingly a delayed progression of adenomas. This latter 
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observation indicates that hypomethylation is more crucial in the early 
development of cancerous tissues and hypermethylation plays a more important 
role as tumour development progresses.  
The hypothesized coherence between DNA methylation and gene 
mutations should be mentioned as well. As described, epigenetic changes have 
a negative impact on the expression and activity of DNA sequence repair 
enzymes. Without sufficient activity of MGMT, mutations of guanine to adenine 
occur, explicitly favouring the oncogenic or tumour suppressor activity, 
respectively, of members of the Ras and the p53 gene family. Furthermore, 
radiation-induced cytosine to thymine mutations and the resulting CpG island 
loss favours the emergence of oncogenic mutations.  
Altogether, there are reasonable arguments for a causal relation 
between aberrant DNA methylation and carcinogenesis. In any case, an 
interface between genetics and epigenetics can be assumed, whereas 
epigenetic aberrations seem to function as a ‘collecting pond’ for environmental 
influences that passes these changes on to gene expression and probably even 
to gene sequences, thus amplifying the origin of exuberantly growing cells. 
However, many more aspects remain to be illuminated to further clarify this 
issue. (BAYLIN & BESTOR, 2002; FEINBERG, 2007) 
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7 EXPERIMENTAL METHODS OF CYTOSINE 
METHYLATION RESEARCH – AN OVERVIEW 
At the beginning of the 1980s, the first methods for analyzing the 
degree of cytosine (C) methylation in DNA samples have been developed. The 
oldest available procedure used high-performance-liquid-chromatography 
(HPLC), followed by the chemical conversion of nucleotides with several 
reagents. The temporal difference of more than 30 years between the first 
occurrence of these methods and the discovery of 5-methyl-cytosine (5mC) 
(HOTCHKISS, 1948) is surprisingly high. However, the methodology of cytosine 
methylation measurement has experienced impressive improvement during the 
last few years and is still expanding. 
The methodology for determining cytosine methylation comprises a 
number of different techniques, but these can be split into two main groups, the 
global methylation analysis and the gene-specific analysis. The latter can 
further be divided into genome-wide and target-gene analysis. (SHEN & 
WATERLAND, 2007) 
There are some crossovers between the two groups, for example the 
use of bisulphite or immunologic methods can be adopted for global and 
specific analysis. Both of them started as being applied in rather general 
experiments, but soon became part of more sequence-specific approaches. To 
allow for this instance, the structure of this chapter is a compromise that does 
not necessarily reflect experimental standard procedures. The procedural 
scheme below (see Fig. 15) provides a good overview about the selection of 
distinct procedures for the respective experimental design. 
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Fig. 15: Experimental decision tree 
Overview of experimental methods for the assessment of DNA methylation 
according to the experiment’s objective; the most important approaches are 
described in the text (SHEN & WATERLAND, 2007) 
7.1 Global approaches 
7.1.1 High performance liquid chromatography 
HPLC-based methods for determining the 5mC content in DNA samples 
have been at the lead to emerge. The early versions of those applied reverse 
phase HPLC. The first step requires treatment of sample DNA with hydrolyzing 
enzymes, like DNAse I, nuclease P1 or phosphodiesterase. Afterwards, the 
processed sample has to be treated with alkaline phosphatase. The released 
deoxyribonucleotides (dNTs) are chromatographically separated and identified 
by UV-light detection of their specific absorbances at 254 and 280 nm. This 
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method has further been improved with mass spectrometric detection. (KUO & 
al., 1980; DEL GAUDIO & al., 1997) 
The amount of DNA sample needed is less than 1 µg, making the 
method suitable for routine measurements, but less practical when only a small 
amount of cells is available. (OAKELEY, 1999) 
7.1.2 Thin layer chromatography 
Thin layer chromatography (TLC) makes use of the restriction enzyme 
MspI that cuts DNA at specific CCGG sites. The phosphate at the 5’ ends of the 
chopped DNA can be labelled by attachment of [γ32P]ATP with a polynucleotide 
kinase. Then the sample is hydrolyzed (see above) and applied onto a 
diethylaminoethyl (DEAE) cellulose plate. (KUCHINO & al., 1987) Common 
solvent compositions are isobutyrate : ammonia : distilled water (66 : 1 : 33) and 
isopropanol : HCl : distilled water (70 : 15 : 15) for the first and second 
dimensional separation, respectively. Parallel to the sample run, a control run 
with labelled C and 5mC should be carried out. The relative occurrence of the C 
to the 5mC spots can be determined by phosphor imaging or related methods. 
Additionally, a second control can be run without MspI digestion to subtract 
possible non-specific signals. 
As with HPLC application this method is limited to qualitative 
measurements and requires appropriate amounts of sample. (OAKELEY, 1999) 
7.1.3 SssI methyl transferase assay 
The SssI methyl transferase assay is used for quantifying small 
changes in global DNA methylation. For this purpose, Tritium-labelled methyl 
groups of SAM are transmitted to unmethylated Cs at CpG sequences. After 
immobilisation of the DNA and washing-off of excessive SAM, the amount of 
incorporated CH3-groups can be measured by scintillation counting. (SCHMITT 
& al., 1997) 
One of the two major drawbacks of this method is the chemical 
instability of both SAM and SssI, typically causing large errors between times or 
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conductors of such an experiment. The other drawback is the challenge of 
completely dissolving DNA. If this is not performed correctly, the scintillation 
count might overlook portions of the DNA involved in the reaction. These 
disadvantages can be allayed by the use of internal standards and the digestion 
with a restriction enzyme that does not affect CpG islands, respectively. 
(OAKELEY, 1999) 
7.1.4 Chloracetaldehyd assay 
The chloracetaldehyde reaction starts with treating the sample DNA 
with sulphuric acid and removing the liberated purines by silver precipitation or 
chromatography. C is then converted to uracil by using sodium bisulphite (see 
below). The following reaction of 5mC with chloracetaldehyde results in an 
ethenocytosine derivate which is highly fluorescent. 
This method contains two major flaws as well. First, it is rather time 
consuming, second, chloracetaldehyde is a toxic reagent. (OAKELEY & al., 
1999) 
7.1.5 Restriction endonuclease approaches 
The use of bacterial restriction enzymes in determining DNA 
methylation is quite common, especially in contexts where simple and cheap 
methods are required. Two such enzymes, HpaII and MspI, can be used in a 
southern blot. These two enzymes are endonucleases and so-called 
isoschizomeres, meaning they cleave DNA at specific recognition sites within a 
given sequence and they have a different sensitivity towards the methylation 
status of the respective site. For both mentioned enzymes the site is CCGG. It 
makes no difference for MspI if the site is methylated or not, but HpaII will 
cleave the site only if it is unmethylated. Depending on the methylation status of 
the cleavage site, a southern blot reveals different bands when the activity of 
both enzymes is compared. Two bands of the same size mean an unmethylated 
sequence and a larger HpaII band means methylation. 
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The disadvantages of this method are its restriction to qualitative 
analyses, the limitation of sample numbers, the relatively large amounts of 
sample needed and the fact that not all methylation in a given genome occurs 
on the cleavage site of the respective endonuclease. (OAKELEY, 1999) 
7.1.6 Immunological approaches 
There are several ways of immunological application in measurements 
of DNA methylation. One method to determine global methylation levels uses 
an antibody against 5mC against which in turn another antibody is used. The 
second antibody is linked to fluorescein-isothiocyanate (FITC). The signal that is 
proportional to the amount of 5mC can be measured fluorometrically. Additional 
ethidium bromide staining can visualize the total amount of DNA on the plate. 
For immobilizing the sample DNA, a DEAE cellulose plate is recommended, 
however, in any case it is necessary to measure the autofluorescence of the 
plate. Before DNA application, the plate is recommended to be washed with a 
solution of 1% Triton X-100 in wash buffer. The same solution should be used 
to wash off excessive antibodies after incubation. (OAKELEY & al., 1997) 
The major flaw of this method is the requirement of 5mC not to pair to 
another base. This is best accomplished by depurination (see above). 
(OAKELEY, 1999) 
7.1.7 The bisulphite approach 
One of the most prominent features of several techniques for 
determining the methylation status of a given DNA sequence is the chemical 
sodium bisulphite. In single-stranded, but not double-stranded DNA, this 
reagent converts C to uracil (U) with high reactivity, whereas 5mC is hardly 
affected. The C6 position of a pyrimidine ring becomes sulphonated and 
subsequently the bond of the amino group at the C4 position in C and 5mC is 
weakened. At a pH optimum of 5.8 both bases will deaminate, however, the 
conversion of C to U is finished before considerable conversion of 5mC to T has 
occurred. During a probably following polymerase chain reaction (PCR) of 
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selected sequences, U is exchanged with T. Afterwards the sequences are 
basically ready for sequence analysis. (HAYATSU & al., 1970; FROMMER & 
al., 1992; OLEK & al., 1996) 
Caution has to be taken in connection with acid-catalyzed loss of 
purines, because this might cause considerable damage to examinable 
sequences. The pH conditions used in such experiments usually do not cause 
remarkable losses, however the incubation time with bisulphite should not 
exceed a few hours. DNA denaturation is best conducted by ‘trapping’ it in 
frozen agarose-gel.  
The bisulphite method alone contains a number of noteworthy flaws. 
Bisulphite conversion may be incomplete or excessive, leading to artifacts in 
both cases. In addition, the complexity of a sequence is reduced because of the 
conversion of C to U, making the primer design more difficult. Furthermore, the 
C to T ratio will most likely not reflect the true 5mC to C ratio in a given 
sequence. Because of these caveats, combinations of the use of bisulphite with 
other methods have been developed. (OAKELEY, 1999; BECK & RAKYAN, 
2008) 
7.1.7.1 Combined bisulphite restriction analysis 
One of the mentioned bisulphite modifications is the combined 
bisulphite restriction analysis (COBRA). For this method, bisulphite conversion 
and PCR amplification are first conducted (see above). The next step is the 
application of two restriction endonucleases. The first one must recognize CpG 
containing sequences as its restriction site. The second is used as a control and 
must recognize a restriction sequence containing C, but not CpG. This 
procedure serves for the determination of possible incomplete conversion or 
methylation at CpNpG sites. If the control is negative, the location of the 
cleavage sites can proceed. (XIONG & LAIRD, 1997) 
This method provides more accuracy than sequencing after bisulphite 
reaction alone, but it is still limited to specific restriction sites and can probably 
not capture the complete methylome of a given sequence. (OAKELEY, 1999; 
SHEN & WATERLAND, 2007) 
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7.2 Sequence-specific approaches 
7.2.1 The permanganate / hydrazine approach 
The first reported chemical reactions to modify methylation-related 
bases involved hydrazine and permanganate. Hydrazine breaks DNA at C and 
T residues, whereas permanganate oxidizes 5mC and T residues. Subsequent 
pyridinolysis breaks the DNA at those oxidized residues. The break parts can 
then undergo a so-called ligation-mediated PCR for later sequencing. 
Therefore, a gene-specific primer and a linker that binds to the hydrazine or 
permanganate site of fracture are added to the sample. The DNA sequence 
between the primer and the linker is replicated by PCR. After sequencing, e. g. 
on a gel, a methylation pattern can be determined. (MAXAM & GILBERT, 1980; 
FRITZSCHE & al., 1987; PFEIFER & al., 1989) 
It should be noted that the permanganate reaction is more variable and 
provides less clear information than the hydrazine reaction. (OAKELEY, 1999) 
7.2.2 Methylation-sensitive single nucleotide primer 
extension 
Another modification of bisulphite-based methods is the methylation-
sensitive single nucleotide primer extension (MS-SNuPE) method. Bisulphite 
reaction and PCR are carried out as usual and the amplification product is 
purified by gel-electrophoresis. Afterwards, a specific primer is added which 
should attach to the amplified sequence in 5’ direction immediately next to the 
opposite strand’s C residue in question. For the following primer extension 
reaction, either [32P]-labelled cytidine triphosphate or the equally labelled 
thymidine triphosphate is added. The outcome can be measured by 
denaturating the strand on a gel and phosphor imaging of the elongated primer. 
Depending on the original methylation status of the examined C residue, either 
the labelled C or the labelled T will show a signal. (GONZALGO & JONES, 
1997) 
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7.2.3 Bisulphite pyrosequencing 
Bisulphite pyrosequencing is an advanced technique of bisulphite 
conversion and PCR. Hereby, a biotinylated primer is aligned to the amplified 
conversion product. Alternatively, a specific primer together with a biotinylated 
primer can be used. The result should in any case be single-stranded DNA for 
the following reaction. The basis of this method is the luciferase reaction 
creating measurable light after processing luciferin to oxyluciferin with ATP. The 
production of ATP is catalyzed by the enzyme ATP sulfurylase which uses the 
liberated pyrophosphate (PPi) after nucleotide adherence to the DNA strand. 
The reaction chemicals next to the processed DNA sample are luciferin, 
luciferase, DNA-polymerase, apyrase, ATP sulfurylase and adenosine-5’-
monophosphate (APS) as the substrate for ATP production. In the next step, 
nucleotide triphosphates are added one by one. If one of these can be added to 
the primer or synthesized DNA strand because of a fitting opposing base, PPi is 
released and the sulfurylase-luciferase reaction is employed. The 
chemiluminescent output is measured and excessive nucleotide triphosphates 
are degraded by apyrase. This method provides a methylation pattern of the 
examined DNA sequence in comparison to the same sequence that has not 
been bisulphite-processed. (COLELLA & al., 2003) 
7.2.4 Microarray-based bisulphite approaches 
The first genome-wide microarray-based method involved the use of 
bisulphite (see above). Application of the amplified product to microarrays with 
original DNA probes reveals the original methylation state of a CpG island. 
Probe design, however, proves difficult because of the reduction of the C 
content of the examined sequence and it is not clear if these methods can be 
used on the whole genome of an organism. 
Nevertheless, they have been improved in the course of their 
development. In one extension not only a specific sequence, but the complete 
sample is amplified after bisulphite reaction, raising the number of identifiable 
CpG islands. Another extension is the application of bisulphite-treated DNA to 
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microarrays with probes complementary to the converted sequence. (BECK & 
RAKYAN, 2008) 
7.2.5 Microarray-based non-bisulphite approaches 
Array-based methods without bisulphite conversion use a combination 
of restriction enzymes, either methylation-specific or non-specific. Because of 
the non-existent conversion of C to T, these methods offer a wider genomic 
range to be analysed. The constraint therefore is that only the restriction 
sequences can be analyzed, but probably not a complete genome.  
An advancement of the non-bisulphite array-based method uses the 
affinity of some proteins to restriction sequences with methylated DNA, 
especially 5mC in methylated CpG islands. One of these methods is the CpG 
island recovery assay (MIRA) which purifies methylated sequences on a column 
with the respective binding proteins, e. g. MeCP2. This method is suited for 
identification of different methylation marks in cancer. (RAUCH & PFEIFER, 
2005) 
7.2.5.1 Methylated DNA immunoprecipitation / Methylcytosine 
immunoprecipitation 
Two methods, methylated DNA immunoprecipitation (MeDIP) and 
methylcytosine immunoprecipitation (mCIP), make use of antibodies directed 
against 5mC. The precipitate is applied to a microarray. Immunoprecipitation 
does not show resolution below a few hundred basepairs, however, methylated 
CpG islands at close quarters in a given sequence can sum up to about 1000 
base pairs. This and the independence from bisulphite conversion and 
methylation-specific restriction enzymes probably make this application the 
most sensitive of all array-based methods. (WEBER & al., 2005; KESHET & al., 
2006) 
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7.2.6 Restriction landmark genome scanning 
Restriction landmark genome scanning (RLGS) was the first location-
specific method to be used in methylation analysis. Restriction enzymes that 
recognize methylated sites split up DNA samples which are then separated by 
two-dimensional gel-electrophoresis.  
Although the sensitivity is limited because measureable effects can only 
be observed at 30% methylation or higher, the detection of numerous different 
methylation profiles at certain loci is possible. Based on this method, different 
methylation patterns in various normal tissues in comparison to cancerous 
tissues have been reported. (COSTELLO & al., 2002; SHEN & WATERLAND, 
2008) 
7.2.7 Methylation-specific digital karyotyping 
A method similar to RLGS is the methylation-specific digital karyotyping 
(MSDK). Methylation-specific restriction enzymes are used as well, followed by 
another step of fractional digestion by a restriction enzyme. Eventually, the 
pieces of DNA are sequenced and mapped. Sensitivity is about as high as in 
RLGS. (HU & al., 2005) 
7.2.8 Methylation sensitive PCR 
Methylation analysis has seen the employment of a specialised version 
of PCR. The methylation sensitive PCR (MSP) is based on primers that bind on 
either methylated or unmethylated sites. This way, differences in the 
methylation status of paternal and maternal alleles of a gene can be 
determined, however, only on a qualitative basis. Real time PCR-like methods 
have been developed, but quantitative analysis is limited to either strongly 
methylated or almost unmethylated sequences. (HERMAN & al., 1996; 
ZESCHNIGK & al., 2004) 
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7.2.9 Mass spectrometric approaches  
The method for general mass spectrometry (MS) is relatively simple. A 
DNA sample is hydrolyzed and derivatized with a reagent, mainly N-methyl-N-
(tert-butyldimethylsilyl) trifluoroacetamide + 1% tert-butyldimethylchlorosilane 
(MTBSTFA + 1%TBDMCS). The volatile derivatisation products of nucleotides 
can be separated and analyzed by GC-MS, whereas C and 5mC show distinct 
retention times and ion fragment patterns. (SAN ROMERIO & al., 2005; 
GLAVIN & al., 2006) 
An approach that has proved useful for the determination of single 
nucleotide polymorphisms (SNPs) makes use of MALDI mass spectrometry and 
with some extensions has been presented for the analysis of general and 
location-specific DNA methylation patterns. The actual MALDI application 
comes into play in connection with the GOOD assay for SNP determination. 
(SAUER & al., 2000) This assay is based on primer extension (see above) for 
allele distinction and MALDI-MS is typically used for analysis. Together with the 
bisulphite method, this assay is able to determine the methylation status of 
various CpG positions within a given sequence, e. g. a promoter or an intron, in 
a relatively precise way. (TOST & al., 2003) 
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8 CONCLUSION 
The present work provides a survey of the most important issues in 
connection with DNA methylation. Clearly, this topic and epigenetics in general 
have for the last few decades up to date been relevant research fields in 
molecular biology and medicine. New experimental methods have been 
developed and crucial results have been yielded. And yet many more results 
are to be expected, because the momentary knowledge on DNA methylation 
might cover only a diminutive part of the processes going on in a cell nucleus. In 
any case it can be regarded certain that the exclusive knowledge of nucleotide 
sequences and divergent mutations will not be sufficient to establish an 
adequate model for the developmental background of an organism. The same 
is true for the treatment of human disease. During the past few years, 
alterations of genetic events beyond the DNA sequence have gained 
considerable attention and a wave of clinical results for a new level of treatment 
may be expected.  
Among the prospects in regard of human disease, epigenetic therapy in 
cancer appears to provide a most promising outlook. Several drugs have been 
developed, although only the fewest of them have already been permitted for 
clinical application. However, doctors and patients have to mind some 
limitations. Cancer is stated to be a highly multicausal health problem with a 
variety of possible origins, peculiarities and consequences. Therefore, directed 
interruption of methylation metabolism will most probably be only one innovative 
way of treatment, but not the sole cure. Even though a decent portion of hope is 
put into the medical treatment of such diseases, the enormous potential of a 
preventive lifestyle is never to be underestimated.  
Moreover, epigenetic research and techniques may provide a solid 
base for stem cell research. The discussion of a potential role of stem cells in 
cancer development has been discussed (see according chapter) and more 
data can be expected. The isolation of adult stem cells and the retransformation 
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of differentiated cells to a pluripotent embryonic stem cell status will also be an 
interesting issue. Regulation of DNA methylation seems to play a role here as 
well.  
Developmental records of humans and other organisms can be 
achieved by keeping track of epigenetic profiles and the changes that these are 
subject to. Therefore, insights into the epigenetic relevance of physiological and 
pathological phenomena like ageing, disease or the different development of 
twins may be looked forward to. 
And last but not least, in the face of this year’s 150th birthday of 
Darwin’s famous publication “On the Origin of Species” some revelations of the 
evolutionary context of epigenetics and especially DNA methylation may be 
encouraged as well. 
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10 ABSTRACT 
One of the most investigated epigenetic mechanisms is the methylation 
of DNA. This survey is concentrated on cytosine methylation which concerns a 
variety of organisms. 5-methyl-cytosine (5mC) mainly occurs in clusters of 
cytosine and guanine, so-called CpG islands. In plants CpNpG islands are also 
found, whereas N stands for any nucleotide. CpG islands can occur in a mosaic 
pattern or be spread across the genome. The methylation of cytosine is 
basically associated with gene silencing. 
5mC does not exist as a ready nucleobase for DNA synthesis. Rather 
than that, a variety of enzymes catalyzes the transfer of a methyl group from 
their co-enzyme S-adenosyl-L-methionine (SAM) to a target cytosine position 
within the genome. These enzymes are basically divided into three families 
which are DNMT1, DNMT2 and DNMT3. Plants contain an additional family, 
termed chromomethylases (CMTs). The removal of the methylated state of 
cytosine is accomplished by nucleotide excision. 
Several nutrients can provide the requisite methyl group. One of them is 
methionine itself, as a part of SAM. Others are folic acid, cobalamine and 
choline.  
Epigenetic phenomena based on cytosine methylation are genomic 
imprinting and the formation of metastable epialleles. Marks of genomic 
imprinting are set during gametogenesis and early embryonal development. 
One allele of certain genes is deactivated while the other is normally expressed, 
depending on its parental origin. Metastable epialleles are formed during 
embryogenesis and fetal growth.  Their formation is influenced by the nutrient 
composition provided by the mother organism. In general, this applies to genes 
containing an insertion. A high methylation of this insertion can cause 
considerable phenotypical and physiological alterations. 
Among civilisation diseases, cancer is currently the most popular object 
of examination in connection with epigenetic mechanisms. Several biomarkers 
Chapter 10 - Abstract 
 
77 
and related genes have been identified and the development and clinical testing 
of efficient drugs is currently in progress. It is also hypothesized that degenerate 
stem cells play a role in cancer development. In any case there is, however, 
some concern about the succession of changing epigenetic phenomena and the 
development of a tumour. There are some arguments that epigenetic alterations 
may be merely consequences after a somatic cell has proceeded to its 
cancerous state. 
An overview of the current methodology concerning DNA methylation 
research is given in the last chapter. 
 
 
Eine der am meisten erforschten epigenetischen Mechanismen ist die 
Methylierung von DNA. Diese Arbeit beschränkt sich auf die Cytosin-
Methylierung, von der eine Vielfalt an Organismen betroffen ist. Das 
hauptsächliche Vorkommen von 5-Methyl-Cytosin (5mC) besteht in 
Anhäufungen von Cytosin und Guanin, sogenannten CpG-Inseln. In Pflanzen 
findet man auch CpNpG-Inseln vor, wobei N für ein beliebiges Nukleotid steht. 
CpG-Inseln können mosaikartig verteilt oder über das gesamte Genom 
verstreut sein. Die Methylierung von Cytosin wird gemeinhin mit der 
Funktionsstille eines Gens in Verbindung gebracht. 
5mC kommt nicht als Baustein für die DNA vor. Stattdessen katalysiert 
eine Vielzahl an Enzymen den Transfer einer Methylgruppe vom gemeinsamen 
Coenzym S-Adenosyl-L-Methionin (SAM) auf das jeweilige Ziel-Cytosin 
innerhalb des Genoms. Diese Enzyme werden grundsätzlich in drei Klassen 
eingeteilt, welche DNMT1, DNMT2, sowie DNMT3 genannt werden. Pflanzen 
enthalten eine zusätzliche Klasse, die sogenannten Chromomethylasen 
(CMTs). Die Entfernung des Methylierungsstatus erfolgt mittels Ausschnitt des 
ganzen Nukleotids.  
Unterschiedliche Nährstoffe liefern die notwendige Methylgruppe. Einer 
davon ist Methionin direkt, als Bestandteil von SAM. Andere sind Folsäure, 
Cobalamin und Cholin. 
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Epigenetische Vorgänge, die auf Cytosin-Methylierung beruhen, sind 
genomisches ‚imprinting’ und die Formierung von metastabilen Epiallelen. 
‚Imprint’-Markierungen werden im Zuge der Genese von Keimzellen und im 
früh-embryonalen Stadium reguliert. Dabei ist ein Allel eines bestimmten Gens 
deaktiviert, während das andere normal exprimiert wird. Welches Allel 
exprimiert wird, ist abhängig von dessen elterlicher Herkunft. Metastabile 
Epiallele bilden sich während der Embryonal- und Fötalentwicklung. Ihre 
Bildung ist von der Nährstoffzusammensetzung durch den Mutterorganismus 
abhängig. Allgemein sind Gene mit einer Insertion betroffen. Ein hoher 
Methylierungsgrad dieser Insertion kann beträchtliche phänotypische und 
physiologische Änderungen bewirken.  
Unter den Zivilisationskrankheiten wird der Krebs momentan vorrangig 
im Zusammenhang mit epigenetischen Mechanismen untersucht. Mehrere 
Biomarker und damit in Beziehung stehende Gene sind identifiziert worden und 
die Entwicklung und klinische Erprobung von Medikamenten schreitet voran. 
Allerdings bestehen in jedem Fall Bedenken bezüglich der Abfolge von sich 
verändernden epigenetischen Erscheinungen und der Entstehung eines 
Tumors. Es gibt einige Ansätze, die dafür sprechen, dass epigenetische 
Veränderungen nur die Folge sind, nachdem sich eine somatische Zelle zu 
einer Krebszelle entwickelt hat. 
Das letzte Kapitel der vorliegenden Arbeit gibt einen Überblick über die 
aktuelle Methodik bezüglich der DNA-Methylierungsforschung. 
  
 Thomas HABENSCHUSS 
 
 
 
Curriculum Vitae 
 
 
KONTAKTDATEN 
 
Wohnort: Hermanngasse 2a/110, 1070 Wien 
Telefon: +43/681 10 72 27 73 
E-Mail: thomas.habenschuss@oeh.univie.ac.at   
 
 
PERSÖNLICHE DATEN 
 
Geburtsdatum: 30. November 1982 
Staatsbürgerschaft: Österreich 
 
 
AUSBILDUNG: 
 
Momentane Situation: Abschluss der Diplomarbeit zum  
Thema Epigenetik/DNA-Methylierung   
 
Studium der Ernährungswissenschaft a. d. Universität Wien  Wien, seit Oktober 2003  
Ius-Studium a. d. Johannes-Keppler-Universitat Linz  Linz, 2002 - 2003 
 
Matura       Linz, Juli 2001 
AHS Aloisianum      Linz, 1993 - 2001 
Volksschule St. Martin      St. Martin, 1989 - 1993 
 
 
AUSBILDUNGSRELEVANTE PRAKTIKA: 
 
Institut für allgemeine Lebensmittelchemie:   Łódź (Polen), Juli & August 
2008 
(Technische Universität Łódź, Polen) 
Anwendung unterschiedlicher Fluoreszenz-Methoden &  
EDV-gestützter „molecular modelling“ – Methoden 
für Bio-Wissenschaften, Verfassen eines Artikels über 
das abgeschlossene Projekt 
 
Institut für Medizinische Chemie:    Wien, Februar bis Juni 2008 
(Medizinuniversität Wien) 
Projektarbeit zum Thema „Einfluss verschiedener  
Differenzierungsmethoden auf den Frataxin-Stoffwechsel 
in der Zellinie K562“ 
 
Institut für Ernährung:      Wien, September 2007 
(Veterinärmedizinische Universität Wien)  
Anwendung von Analysemethoden, Literaturrecherche, 
Vorbereitung von Präsentationen 
 
 
 
  
 
Otto-Wagner-Spital:     Wien, Juli 2007 
Erhebung von Ernährungs- und Demenzzustand, sowie 
anthropometrische Messungen im Zuge der Studie  
“Nutritional risk patients in geriatric long-term care” 
 
Institut für Medizinische Chemie:    Wien, Februar 2007 
(Medizinuniversität Wien) 
Anwendung von Analysemethoden, Vorbereitung von 
Lehrmaterial, Teilnahme an einem wissenschaftlichen 
Kongress 
 
Institut für Ernährungswissenschaften:   Wien, September 2006 
(Universität Wien) 
Anwendung von Analysemethoden, Literaturrecherche,  
Teilnahme und Mithilfe bei einem internationalen  
wissenschaftlichen Kongress 
 
 
WEITERE PRAKTISCHE ERFAHRUNGEN: 
 
Tutor a. d. Medizinischen Universität Wien   Wien, Oktober 2008 – Januar 
2009 
(Betreuung von Laborübungen im Medizincurriculum) 
 
Studienvertreter a. d. Universität Wien    Wien, seit Juli 2007 
 
Mitarbeiter der Studienvertretung a. d.    Wien, 2003 – 2007 
Universität Wien 
 
Administrative Tätigkeiten bei Chilli Business Services  Linz, seit Dezember 2003 
 
Zivildienst am AKH Linz     Linz, 2001 - 2002 
(Abteilung Onkologie & Abteilung Optisches Archiv) 
 
 
SONSTIGE KENNTNISSE: 
 
Fremdsprachen: Englisch (sehr gut), Französisch (Grundlagen), Spanisch (Grundlagen), Polnisch 
(Grundlagen) 
 
EDV-Kenntnisse: MS Office (Word, Excel, PowerPoint), SPSS (Statistikprogramm), HyperChem 
& GaussianView (molecular-modelling-Programme), Adobe Photoshop & InDesign 
(Graphikprogramme) 
 
 
INTERESSENSGEBIETE: 
 
Sport, Ernährung, Literatur, Philosophie & Wissenschaftstheorie, Bildungs- & Gesundheitspolitik 
 
 
Wien, 1. Februar 2009 
 
Thomas Habenschuss 
